US20040175723A1 - TaqManTM-PCR for the detection of pathogenic E.coli strains - Google Patents
TaqManTM-PCR for the detection of pathogenic E.coli strains Download PDFInfo
- Publication number
- US20040175723A1 US20040175723A1 US10/684,085 US68408503A US2004175723A1 US 20040175723 A1 US20040175723 A1 US 20040175723A1 US 68408503 A US68408503 A US 68408503A US 2004175723 A1 US2004175723 A1 US 2004175723A1
- Authority
- US
- United States
- Prior art keywords
- primers
- coli
- hybridise
- toxin
- atg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000588724 Escherichia coli Species 0.000 title claims abstract description 234
- 238000001514 detection method Methods 0.000 title claims abstract description 81
- 230000001717 pathogenic effect Effects 0.000 title claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 51
- 238000012408 PCR amplification Methods 0.000 claims abstract description 17
- 239000003155 DNA primer Substances 0.000 claims abstract description 4
- 239000013615 primer Substances 0.000 claims description 106
- 108700012359 toxins Proteins 0.000 claims description 87
- 239000003053 toxin Substances 0.000 claims description 83
- 108090000623 proteins and genes Proteins 0.000 claims description 81
- 231100000765 toxin Toxicity 0.000 claims description 81
- 239000013612 plasmid Substances 0.000 claims description 65
- 108020004414 DNA Proteins 0.000 claims description 64
- 239000000523 sample Substances 0.000 claims description 64
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 38
- 239000002751 oligonucleotide probe Substances 0.000 claims description 38
- 101150107911 eae gene Proteins 0.000 claims description 31
- 230000003321 amplification Effects 0.000 claims description 28
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 28
- 239000000975 dye Substances 0.000 claims description 24
- 230000000688 enterotoxigenic effect Effects 0.000 claims description 24
- 239000000304 virulence factor Substances 0.000 claims description 18
- 230000007923 virulence factor Effects 0.000 claims description 18
- 208000015181 infectious disease Diseases 0.000 claims description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 10
- 230000000369 enteropathogenic effect Effects 0.000 claims description 9
- 125000003729 nucleotide group Chemical group 0.000 claims description 9
- 230000015556 catabolic process Effects 0.000 claims description 7
- 238000006731 degradation reaction Methods 0.000 claims description 7
- COCMHKNAGZHBDZ-UHFFFAOYSA-N 4-carboxy-3-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]benzoate Chemical group C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(C([O-])=O)=CC=C1C(O)=O COCMHKNAGZHBDZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000000137 annealing Methods 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 108060002716 Exonuclease Proteins 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 5
- 102000013165 exonuclease Human genes 0.000 claims description 5
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 5
- 101100126882 Caenorhabditis elegans kcc-3 gene Proteins 0.000 claims description 4
- 238000011109 contamination Methods 0.000 claims description 4
- 238000007796 conventional method Methods 0.000 claims description 4
- 235000013372 meat Nutrition 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 235000013311 vegetables Nutrition 0.000 claims description 2
- 241001646719 Escherichia coli O157:H7 Species 0.000 description 19
- 108010017898 Shiga Toxins Proteins 0.000 description 19
- 230000001018 virulence Effects 0.000 description 19
- 206010012735 Diarrhoea Diseases 0.000 description 18
- 101100500479 Hafnia alvei eaeA gene Proteins 0.000 description 18
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 18
- 238000003556 assay Methods 0.000 description 17
- 239000000047 product Substances 0.000 description 15
- 241000305071 Enterobacterales Species 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 13
- 206010014896 Enterocolitis haemorrhagic Diseases 0.000 description 13
- 238000002955 isolation Methods 0.000 description 12
- 108010006785 Taq Polymerase Proteins 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 8
- 229920001817 Agar Polymers 0.000 description 7
- 238000009835 boiling Methods 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 241001333951 Escherichia coli O157 Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 238000000246 agarose gel electrophoresis Methods 0.000 description 6
- 235000015278 beef Nutrition 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000002987 primer (paints) Substances 0.000 description 6
- 239000003298 DNA probe Substances 0.000 description 5
- 108010090763 Shiga Toxin 2 Proteins 0.000 description 5
- 239000011543 agarose gel Substances 0.000 description 5
- 230000001351 cycling effect Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 4
- 101710187783 Adherence factor Proteins 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 108010041052 DNA Topoisomerase IV Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 239000000147 enterotoxin Substances 0.000 description 4
- 231100000655 enterotoxin Toxicity 0.000 description 4
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 4
- 229960005542 ethidium bromide Drugs 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000002906 microbiologic effect Effects 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 108020003215 DNA Probes Proteins 0.000 description 3
- 101710146739 Enterotoxin Proteins 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 101710121697 Heat-stable enterotoxin Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000000721 bacterilogical effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000012864 cross contamination Methods 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 239000002619 cytotoxin Substances 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000000405 serological effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000011895 specific detection Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108020000946 Bacterial DNA Proteins 0.000 description 2
- 206010012742 Diarrhoea infectious Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 101150013573 INVE gene Proteins 0.000 description 2
- DXUJSRIVSWEOAG-NAKRPEOUSA-N Ile-Arg-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CS)C(=O)O)N DXUJSRIVSWEOAG-NAKRPEOUSA-N 0.000 description 2
- HAQLBBVZAGMESV-IHRRRGAJSA-N Met-Lys-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O HAQLBBVZAGMESV-IHRRRGAJSA-N 0.000 description 2
- 101100068676 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) gln-1 gene Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 2
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 235000019987 cider Nutrition 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000000741 diarrhetic effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 108010028810 enterohemolysin Proteins 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 208000007475 hemolytic anemia Diseases 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 101150110811 parC gene Proteins 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 235000015277 pork Nutrition 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000011896 sensitive detection Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 101150076562 virB gene Proteins 0.000 description 2
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- ZKEHTYWGPMMGBC-XUXIUFHCSA-N Ala-Leu-Leu-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O ZKEHTYWGPMMGBC-XUXIUFHCSA-N 0.000 description 1
- MTYLORHAQXVQOW-AVGNSLFASA-N Arg-Lys-Met Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(O)=O MTYLORHAQXVQOW-AVGNSLFASA-N 0.000 description 1
- FRBAHXABMQXSJQ-FXQIFTODSA-N Arg-Ser-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O FRBAHXABMQXSJQ-FXQIFTODSA-N 0.000 description 1
- JKRPBTQDPJSQIT-RCWTZXSCSA-N Arg-Thr-Met Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O JKRPBTQDPJSQIT-RCWTZXSCSA-N 0.000 description 1
- XWGJDUSDTRPQRK-ZLUOBGJFSA-N Asn-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O XWGJDUSDTRPQRK-ZLUOBGJFSA-N 0.000 description 1
- FGYUMGXLCZYNQG-UBHSHLNASA-N Asn-Cys-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)N)C(O)=O)=CNC2=C1 FGYUMGXLCZYNQG-UBHSHLNASA-N 0.000 description 1
- JEEFEQCRXKPQHC-KKUMJFAQSA-N Asn-Leu-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JEEFEQCRXKPQHC-KKUMJFAQSA-N 0.000 description 1
- MYVBTYXSWILFCG-BQBZGAKWSA-N Asn-Met-Gly Chemical compound CSCC[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC(=O)N)N MYVBTYXSWILFCG-BQBZGAKWSA-N 0.000 description 1
- WJHYGGVCWREQMO-GHCJXIJMSA-N Asp-Cys-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WJHYGGVCWREQMO-GHCJXIJMSA-N 0.000 description 1
- RQHLMGCXCZUOGT-ZPFDUUQYSA-N Asp-Leu-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O RQHLMGCXCZUOGT-ZPFDUUQYSA-N 0.000 description 1
- BWJZSLQJNBSUPM-FXQIFTODSA-N Asp-Pro-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O BWJZSLQJNBSUPM-FXQIFTODSA-N 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000589994 Campylobacter sp. Species 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 241000588919 Citrobacter freundii Species 0.000 description 1
- 241000873310 Citrobacter sp. Species 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NDUSUIGBMZCOIL-ZKWXMUAHSA-N Cys-Asn-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CS)N NDUSUIGBMZCOIL-ZKWXMUAHSA-N 0.000 description 1
- OTXLNICGSXPGQF-KBIXCLLPSA-N Cys-Ile-Glu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O OTXLNICGSXPGQF-KBIXCLLPSA-N 0.000 description 1
- HBHMVBGGHDMPBF-GARJFASQSA-N Cys-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CS)N HBHMVBGGHDMPBF-GARJFASQSA-N 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 241000147019 Enterobacter sp. Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000025053 Escherichia coli DSM 30083 = JCM 1649 = ATCC 11775 Species 0.000 description 1
- 206010061126 Escherichia infection Diseases 0.000 description 1
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
- 206010053172 Fatal outcomes Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- FAQVCWVVIYYWRR-WHFBIAKZSA-N Gln-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O FAQVCWVVIYYWRR-WHFBIAKZSA-N 0.000 description 1
- XSBGUANSZDGULP-IUCAKERBSA-N Gln-Gly-Lys Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(O)=O XSBGUANSZDGULP-IUCAKERBSA-N 0.000 description 1
- UWKPRVKWEKEMSY-DCAQKATOSA-N Gln-Lys-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O UWKPRVKWEKEMSY-DCAQKATOSA-N 0.000 description 1
- VEYGCDYMOXHJLS-GVXVVHGQSA-N Gln-Val-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O VEYGCDYMOXHJLS-GVXVVHGQSA-N 0.000 description 1
- VNCNWQPIQYAMAK-ACZMJKKPSA-N Glu-Ser-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O VNCNWQPIQYAMAK-ACZMJKKPSA-N 0.000 description 1
- FJWSJWACLMTDMI-WPRPVWTQSA-N Gly-Met-Val Chemical compound [H]NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(O)=O FJWSJWACLMTDMI-WPRPVWTQSA-N 0.000 description 1
- YABRDIBSPZONIY-BQBZGAKWSA-N Gly-Ser-Met Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(O)=O YABRDIBSPZONIY-BQBZGAKWSA-N 0.000 description 1
- FFALDIDGPLUDKV-ZDLURKLDSA-N Gly-Thr-Ser Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O FFALDIDGPLUDKV-ZDLURKLDSA-N 0.000 description 1
- ATXGFMOBVKSOMK-PEDHHIEDSA-N Ile-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N ATXGFMOBVKSOMK-PEDHHIEDSA-N 0.000 description 1
- YKRIXHPEIZUDDY-GMOBBJLQSA-N Ile-Asn-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YKRIXHPEIZUDDY-GMOBBJLQSA-N 0.000 description 1
- JDAWAWXGAUZPNJ-ZPFDUUQYSA-N Ile-Glu-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N JDAWAWXGAUZPNJ-ZPFDUUQYSA-N 0.000 description 1
- UWBDLNOCIDGPQE-GUBZILKMSA-N Ile-Lys Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN UWBDLNOCIDGPQE-GUBZILKMSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000019637 Infantile Diarrhea Diseases 0.000 description 1
- 101710167241 Intimin Proteins 0.000 description 1
- LZDNBBYBDGBADK-UHFFFAOYSA-N L-valyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C(C)C)C(O)=O)=CNC2=C1 LZDNBBYBDGBADK-UHFFFAOYSA-N 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- KWTVLKBOQATPHJ-SRVKXCTJSA-N Leu-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(C)C)N KWTVLKBOQATPHJ-SRVKXCTJSA-N 0.000 description 1
- WGNOPSQMIQERPK-UHFFFAOYSA-N Leu-Asn-Pro Natural products CC(C)CC(N)C(=O)NC(CC(=O)N)C(=O)N1CCCC1C(=O)O WGNOPSQMIQERPK-UHFFFAOYSA-N 0.000 description 1
- IWTBYNQNAPECCS-AVGNSLFASA-N Leu-Glu-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 IWTBYNQNAPECCS-AVGNSLFASA-N 0.000 description 1
- HYIFFZAQXPUEAU-QWRGUYRKSA-N Leu-Gly-Leu Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(C)C HYIFFZAQXPUEAU-QWRGUYRKSA-N 0.000 description 1
- POZULHZYLPGXMR-ONGXEEELSA-N Leu-Gly-Val Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O POZULHZYLPGXMR-ONGXEEELSA-N 0.000 description 1
- AUNMOHYWTAPQLA-XUXIUFHCSA-N Leu-Met-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O AUNMOHYWTAPQLA-XUXIUFHCSA-N 0.000 description 1
- VTJUNIYRYIAIHF-IUCAKERBSA-N Leu-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O VTJUNIYRYIAIHF-IUCAKERBSA-N 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- FACUGMGEFUEBTI-SRVKXCTJSA-N Lys-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CCCCN FACUGMGEFUEBTI-SRVKXCTJSA-N 0.000 description 1
- LPAJOCKCPRZEAG-MNXVOIDGSA-N Lys-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCCCN LPAJOCKCPRZEAG-MNXVOIDGSA-N 0.000 description 1
- QZPXMHVKPHJNTR-DCAQKATOSA-N Met-Leu-Asn Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O QZPXMHVKPHJNTR-DCAQKATOSA-N 0.000 description 1
- AXHNAGAYRGCDLG-UWVGGRQHSA-N Met-Lys-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O AXHNAGAYRGCDLG-UWVGGRQHSA-N 0.000 description 1
- RMLLCGYYVZKKRT-CIUDSAMLSA-N Met-Ser-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O RMLLCGYYVZKKRT-CIUDSAMLSA-N 0.000 description 1
- 206010027527 Microangiopathic haemolytic anaemia Diseases 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- AJHCSUXXECOXOY-UHFFFAOYSA-N N-glycyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-UHFFFAOYSA-N 0.000 description 1
- 108010066427 N-valyltryptophan Proteins 0.000 description 1
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 1
- 101100406879 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) par-2 gene Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- YKUGPVXSDOOANW-KKUMJFAQSA-N Phe-Leu-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O YKUGPVXSDOOANW-KKUMJFAQSA-N 0.000 description 1
- CGBYDGAJHSOGFQ-LPEHRKFASA-N Pro-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 CGBYDGAJHSOGFQ-LPEHRKFASA-N 0.000 description 1
- XQLBWXHVZVBNJM-FXQIFTODSA-N Pro-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 XQLBWXHVZVBNJM-FXQIFTODSA-N 0.000 description 1
- SBVPYBFMIGDIDX-SRVKXCTJSA-N Pro-Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1N(C(=O)[C@H]2NCCC2)CCC1 SBVPYBFMIGDIDX-SRVKXCTJSA-N 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607149 Salmonella sp. Species 0.000 description 1
- ZUGXSSFMTXKHJS-ZLUOBGJFSA-N Ser-Ala-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O ZUGXSSFMTXKHJS-ZLUOBGJFSA-N 0.000 description 1
- YIUWWXVTYLANCJ-NAKRPEOUSA-N Ser-Ile-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O YIUWWXVTYLANCJ-NAKRPEOUSA-N 0.000 description 1
- MQQBBLVOUUJKLH-HJPIBITLSA-N Ser-Ile-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MQQBBLVOUUJKLH-HJPIBITLSA-N 0.000 description 1
- FUMGHWDRRFCKEP-CIUDSAMLSA-N Ser-Leu-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O FUMGHWDRRFCKEP-CIUDSAMLSA-N 0.000 description 1
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 1
- KCNSGAMPBPYUAI-CIUDSAMLSA-N Ser-Leu-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O KCNSGAMPBPYUAI-CIUDSAMLSA-N 0.000 description 1
- IAORETPTUDBBGV-CIUDSAMLSA-N Ser-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N IAORETPTUDBBGV-CIUDSAMLSA-N 0.000 description 1
- RWDVVSKYZBNDCO-MELADBBJSA-N Ser-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CO)N)C(=O)O RWDVVSKYZBNDCO-MELADBBJSA-N 0.000 description 1
- CUXJENOFJXOSOZ-BIIVOSGPSA-N Ser-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CO)N)C(=O)O CUXJENOFJXOSOZ-BIIVOSGPSA-N 0.000 description 1
- PCJLFYBAQZQOFE-KATARQTJSA-N Ser-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N)O PCJLFYBAQZQOFE-KATARQTJSA-N 0.000 description 1
- VVKVHAOOUGNDPJ-SRVKXCTJSA-N Ser-Tyr-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O VVKVHAOOUGNDPJ-SRVKXCTJSA-N 0.000 description 1
- ILVGMCVCQBJPSH-WDSKDSINSA-N Ser-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CO ILVGMCVCQBJPSH-WDSKDSINSA-N 0.000 description 1
- 108010091769 Shiga Toxin 1 Proteins 0.000 description 1
- 241000147000 Shigella flexneri 2a Species 0.000 description 1
- 241000607760 Shigella sonnei Species 0.000 description 1
- 241000607758 Shigella sp. Species 0.000 description 1
- 101150006914 TRP1 gene Proteins 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- GKMYGVQDGVYCPC-IUKAMOBKSA-N Thr-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)N GKMYGVQDGVYCPC-IUKAMOBKSA-N 0.000 description 1
- IMULJHHGAUZZFE-MBLNEYKQSA-N Thr-Gly-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O IMULJHHGAUZZFE-MBLNEYKQSA-N 0.000 description 1
- MEJHFIOYJHTWMK-VOAKCMCISA-N Thr-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)O MEJHFIOYJHTWMK-VOAKCMCISA-N 0.000 description 1
- FDQXPJCLVPFKJW-KJEVXHAQSA-N Thr-Met-Tyr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N)O FDQXPJCLVPFKJW-KJEVXHAQSA-N 0.000 description 1
- UQCNIMDPYICBTR-KYNKHSRBSA-N Thr-Thr-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O UQCNIMDPYICBTR-KYNKHSRBSA-N 0.000 description 1
- KVEWWQRTAVMOFT-KJEVXHAQSA-N Thr-Tyr-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O KVEWWQRTAVMOFT-KJEVXHAQSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- FPCIBLUVDNXPJO-XPUUQOCRSA-N Val-Cys-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CS)C(=O)NCC(O)=O FPCIBLUVDNXPJO-XPUUQOCRSA-N 0.000 description 1
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 1
- OWFGFHQMSBTKLX-UFYCRDLUSA-N Val-Tyr-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N OWFGFHQMSBTKLX-UFYCRDLUSA-N 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000607284 Vibrio sp. Species 0.000 description 1
- 241000131891 Yersinia sp. Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 244000037640 animal pathogen Species 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 239000013584 assay control Substances 0.000 description 1
- 101150009149 bfpA gene Proteins 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- UKWLRLAKGMZXJC-QIECWBMSSA-L disodium;[4-chloro-3-[(3r,5s)-1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl]phenyl] phosphate Chemical compound [Na+].[Na+].O1OC2([C@@H]3CC4C[C@H]2CC(Cl)(C4)C3)C1(OC)C1=CC(OP([O-])([O-])=O)=CC=C1Cl UKWLRLAKGMZXJC-QIECWBMSSA-L 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 101150099846 eaeA gene Proteins 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000006153 eosin methylene blue Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 208000020612 escherichia coli infection Diseases 0.000 description 1
- 235000013410 fast food Nutrition 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 239000002271 gyrase inhibitor Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 201000009863 inflammatory diarrhea Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 108010027338 isoleucylcysteine Proteins 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000012092 latex agglutination test Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- 108010003700 lysyl aspartic acid Proteins 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000001459 mortal effect Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 101150093826 par1 gene Proteins 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 108010079317 prolyl-tyrosine Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 201000009881 secretory diarrhea Diseases 0.000 description 1
- 108010071207 serylmethionine Proteins 0.000 description 1
- 229940115939 shigella sonnei Drugs 0.000 description 1
- 239000001984 sorbitol MacConkey agar Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 108010000998 wheylin-2 peptide Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/6823—Release of bound markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
Definitions
- the present invention relates to a rapid, high performance assay for the detection of pathogenic E. coli which is based on TaqManTMPCR technique, and to specific optimised oligonucleotide primers and labelled oligonucleotide probes useful in the assay.
- EHEC Escherichia coli
- HUS hemolytic uremic syndrome
- EHEC In most outbreaks reported, consumption of contaminated ground beef has been the source of infection (5,8,19-22), whereas in Japan raddish sprouts are suspected (10). EHEC has been isolated from cow milk (6,19,23), Water (19), chicken, pork, and apple cider (19,24,25), but also human horizontal smear infections have been reported (15). Cattle appear likely to be the reservoir (22,26). Cross contamination, improper handling, and inadequate cooking all contribute to food-borne infections caused by EHEC. EHEC produce Shiga-like toxins (sit), also known as verotoxins or cytotoxins (12,27).
- EHEC EHEC
- serogroup O157:H7 A large proportion of EHEC have been found to belong to the serogroup O157:H7, but notably, also a variety of EHEC belonging to other serogroups (O22, O26, O55, O111, O114, O145) have been reported especially in Europe (12,15,28-32).
- ETEC enterotoxigenic strains
- EPEC enteropathogenic strains
- EIEC enteroinvasive strains
- EaggEC enteroaggregative strains
- ETEC synthesize heat labile and/or heat stable enterotoxins that can cause a secretory diarrhea (“traveller's diarrhea”) resembling that of Vibrio cholerae (36,42,43).
- Toxin production is plasmid mediated and most commonly involves E. coli serogroups O6, O15, O124, O136, O143, O145, and 0147 (32).
- EPEC cause diarrheal symptoms primarily in infants (32). Although the pathogenesis is unclear, the epithelial degradation of the gut, and the inflammatory response that are observed in tissue sections may be a consequence due to the adhesive properties of the bacterium.
- EIEC strains are capable of penetrating and invading the intestinal epithelial cells and produce an inflammatory diarrhea similar to that caused by Shigella bacteria (38,47,48).
- Fecal smears contain blood, mucus and segmented neutrophils.
- EIEC contain virulence plasmids coding for additional pathogenic factors (48). Serogroups O28, O112, O115, O124, O136, O143, O145, and O147 are most commonly found on EIEC (32).
- EaggEC are associated with persistent diarrhea in children and with traveller's diarrhea. EaggEC are characterized by their adherence capacity that leads to aggregation of Hep-2 cells. This effect is associated with the presence of a virulence plasmid (pCVD432). EaggEC are supected to also produce a heat stable enterotoxin (EAST1) (49-53). They can belong to serogroups O44 and O126 (32).
- EHEC E. coli broth, lauryl sulfate tryptose 4-methylumbelliferyl-b-acid broth, eosin methylene blue agar, McConkey sorbitol agar, and enterohemolysin agar (28,32,54-59). All of these assays, unfortunately, are indirect and lack the ability to identify EHEC or the other pathogenic E. coli strains specifically.
- Several methods for biochemical identification and immunological detection of EHEC have been put forward (54,60-63), however, it is well recognized that pathogenic E. coli strains neither posess nor lack unique fermentation pathways (58,64). Serotyping is not conclusive since no absolute correlation between serotype and pathogenic E. coli group can be established (12,27,32,58,65).
- DNA hybridization techniques have been established for experimental research but are not applicable for large scale routine diagnostic procedures (66,67). DNA amplification based assays, using PCR have been reported (68-72). Limitations to these methods include cumbersome post-PCR detection methods (agarose gel electrophoresis, Biotin/Avidin based ELISA detection systems).
- PCR assay which allows the specific determination of virulence factors characteristic for EHEC, ETEC, EPEC, EIEC, and EaggEC that is based on a fluorigenic detection method of PCR amplification has been developed.
- TAMRA fluorescent quencher dye
- Taq polymerase extends from the specific PCR primer and cleaves the internal, fluorigenic oligonucleotide probe annealed to the template strand.
- the reporter dye and the quencher dye get spatially separated.
- oligonucleotide hydrolysis and physical separation of the reporter and the quencher dyes a measurable increase in fluoresecence intensity at 518 nm can be observed.
- PCR cycling leads to exponential amplification of the PCR product and consequently of fluorescence intensity.
- TaqManTM-PCR is performed in optical tubes that allow measurements of fluorescence signals without opening the PCR tubes. This dramatically minimizes post-PCR processing time and almost completely eliminates cross-PCR contamination problems.
- simultaneous testing of biological materials for the presence of virulence genes of E. coli strains and other enterobacteria, harboring virulence genes can be semiautomated and performed within 18 h.
- TaqManTM-PCR for the detection of pathogenic E. coli is provided, enabling for the first time the specific, rapid and high throughput routine detection of EHEC, ETEC, EFEC, EIEC, and EaggEC and related enterobacteria that harbor these virulence genes in routine bacteriological laboratories.
- the invention then, inter alia, comprises the following alone or in combination:
- a method for the detection of pathogenic E. coli in a sample comprising PCR amplification of DNA isolated from said sample using a set of oligonucleotide primers specific for virulence factors/toxins of pathogenic E. coli selected from
- primers that hybridise to a gene encoding heat labile toxin, or heat stabile toxin for the amplification of a DNA sequence characteristic for enterotoxigenic E. coli primers that hybridise to a gene encoding heat labile toxin, or heat stabile toxin for the amplification of a DNA sequence characteristic for enterotoxigenic E. coli;
- primers that hybridise to a gene encoding heat stabile toxin for the amplification of a DNA sequence characteristic for enteroaggregative E. coli are identical to primers that hybridise to a gene encoding heat stabile toxin for the amplification of a DNA sequence characteristic for enteroaggregative E. coli;
- primers that hybridise to the pCVD432 plasmid for the amplification of a DNA sequence characteristic for enteroaggregative E. coli are identical to the pCVD432 plasmid for the amplification of a DNA sequence characteristic for enteroaggregative E. coli;
- primers that hybridise to the inv-plasmid for the amplification of a DNA sequence contained in enteroinvasive E. coli are identical to primers that hybridise to the inv-plasmid for the amplification of a DNA sequence contained in enteroinvasive E. coli;
- primers that hybridise to the EAF plasmid, or the eae gene for the amplification of a DNA sequence characteristic for enteropathogenic E. coli are also useful as primers that hybridise to the EAF plasmid, or the eae gene for the amplification of a DNA sequence characteristic for enteropathogenic E. coli ; and/or
- primers that hybridise to the genes encoding shiga-like toxin sltI or sltII for the amplification of a DNA sequence characteristic for enterohemorrhagic E. coli followed by detection and identification of the amplified product using conventional methods;
- the set of primers that hybridise to the gene encoding heat labile toxin characteristic for enterotoxigenic E. coli is LT-1: 5′ GCG TTA CTA TCC TCT CTA TGT G 3′ and LT-2: 5′ AGT TTT CCA TAC TGA TTG CCG C 3′;
- the set of primers that hybridise to the gene encoding heat stabile toxin characteristic for enterotoxigenic E. coli is ST-1: 5′ TCC CTC AGG ATG CTA AAC CAG 3′ and ST-2a: 5′ TCG ATT TAT TCA ACA AAG CAA C 3′;
- the set of primers that hybridise for the gene encoding heat stabile toxin characteristic for enteroaggregative E. coli is EASTI-1: 5′ AAC TGC TGG GTA TGT GGC TGG 3′ and EASTI-2: 5′ TGC TGA CCT GCC TCT TCC ATG 3′;
- the set of primers which hybridise to the pCVD432 plasmid is EA-1: 5′ CTG GCG AAA GAC TGT ATC ATT G 3′ and EA-2: 5′ TAA TGT ATA GAA ATC CGC TGT T 3′;
- the set of primers which hybridise to the inv-plasmid is EI-1: 5′ TTT CTG GAT GGT ATG GTG AGG 3′ and EI-2: 5′ CTT GAA CAT AAG GAA ATA AAC 3′;
- EP-1 5′ CAG GGT AAA AGA AAG ATG ATA AG 3′ and EP-2: 5′ AAT ATG GGG ACC ATG TAT TAT C 3′;
- the set of primers which hybridise to the eae gene is EPeh-1: 5′ CCC GGA CCC GGC ACA AGC ATA AG 3′ and EPeh-2: 5′ AGT CTC GCC AGT ATT CGC CAC C 3′;
- the primers which hybridises to the gene encoding shiga-like toxin SltI is SltI-1: 5′ ATG AAA AAA ACA TTA TTA ATA GC 3′ and SltI-2: 5′ TCA CYG AGC TAT TCT GAG TCA AGC 3′; and
- the primers which hybridises to the gene encoding shiga-like toxin SltII is SltII-1: 5′ ATG AAG AAG ATR WTT RTD GCR GYT TTA TTY G 3′ and SltII-2: 5′ TCA GTC ATW ATT AAA CTK CAC YTS RGC AAA KCC 3′
- W is A/T
- R is A/G
- D is A/G/T
- Y is C/T
- K is G/T;
- the labelled oligonucleotide probe for the detection of heat labile toxin characteristic for enterotoxigenic E. coli is
- the labelled oligonucleotide probe for the detection of heat stabile toxin characteristic for enterotoxigenic E. coli is
- the labelled oligonucleotide probe for the detection of heat stabile toxin characteristic for enteroaggregative E. coli is
- the labelled oligonucleotide probe for the detection of the inv-plasmid is;
- the labelled oligonucleotide probe for the detection of the EAF-plasmid is;
- the labelled oligonucleotide probe for the detection of the eae gene is
- the labelled oligonucleotide probe for the detection of shiga-like toxin SltII gene is
- the fluoroscent reporter dye is 6-carboxy- fluoroscein, tetrachloro-6-carboxy-fluoroscein, or hexachloro-6-carboxy- fluoroscein
- the fluorescent quencher dye is 6-carboxytetramethyl- rhodamine
- the method as above wherein the PCR amplification process consists of 35 PCR cycles at a MgCl 2 concentration of 5.2 mmol, an annealing temperature of 55° C. and an extension temperature of 65° C.;
- a set of primers useful for PCR amplification of DNA specific for virulence factors/toxins of pathogenic E. coli selected from:
- the set of primers which hybridise to the gene encoding heat labile toxin of enterotoxigenic E. coli is LT-1: 5′ GCG TTA CTA TCC TCT CTA TGT G 3 and LT-2: 5′ AGT TTT CCA TAC TGA TTG CCG C 3′;
- the set of primers which hybridise to the gene encoding heat stabile toxin of enterotoxigenic E. coli is ST-1: 5′ TCC CTC AGG ATG CTA AAC CAG 3′ and ST-2a: 5′ TCG ATT TAT TCA ACA AAG CAA C 3′;.
- the set of primers which hybridise to the gene encoding heat stabile toxin of enteroaggregative E. coli is EASTI-1: 5′ AAC TGC TGG GTA TGT GGC TGG 3′ and EASTI-2: 5′ TGC TGA CCT GCC TCT TCC ATG 3′;
- the set of primers which hybridise to the pCVD432 plasmid is EA-1: 5′ CTG GCG AAA GAC TGT ATC ATT G 3′ and EA-2: 5′ TAA TGT ATA GAA ATC CGC TGT T 3′;
- the set of primers which hybridise to the inv-plasmid is EI-1: 5′ TTT CTG GAT GGT ATG GTG AGG 3′ and EI-2: 5′ CTT GAA CAT AAG GAA ATA AAC 3′;
- the set of primers which hybridise to the EAF plasmid is EP-1: 5′ CAG GGT AAA AGA AAG ATG ATA AG 3′ and EP-2: 5′ AAT ATG GGG ACC ATG TAT TAT C 3′;
- the set of primers which hybridise to the eae gene is EPeh-1: 5′ CCC GGA CCC GGC ACA AGC ATA AG 3′ and EPeh-2: 5′ AGT CTC GCC AGT ATT CGC CAC C 3′;
- the set of primers which hybridise to the shiga-like toxin sltI gene is SltI-1: 5′ ATG AAA AAA ACA TTA TTA ATA GC 3′ and SltI-2: 5′ TCA CYG AGC TAT TCT GAG TCA AGC 3′;
- the set of primers which hybridise to the shiga-like toxin sltII is SltII-1: 5′ ATG AAG AAG ATR WTT RTD GCR GYT TTA TTY G 3′ and SltII-2: 5′ TCA GTC ATW ATT AAA CTK CAC YTS RGC AAA KCC 3′
- the set of primers as above which in addition to the primers for amplification of target DNA comprise a labelled oligonucleotide probe which is labelled with a fluoroscent reporter dye, such as 6-carboxy-fluoroscein, tetrachloro-6-carboxy-fluoroscein, hexachloro-6-carboxy-fluoroscein, at the most 5′ base and a fluoroscent quencher dye, such as 6-carboxytetramethyl-rhodamine, at the most 3′ base, and have a nucleotide sequence selected from a fluoroscent reporter dye, such as 6-carboxy-fluoroscein, tetrachloro-6-carboxy-fluoroscein, hexachloro-6-carboxy-fluoroscein, at the most 5′ base and a fluoroscent quencher dye, such as 6-carboxytetramethyl-rhodamine, at the most 3′ base,
- EHEC EHEC
- EPEC EIEC
- ETEC EaggEC
- EaggEC Biochemical properties of EHEC, EPEC, EIEC, ETEC, and EaggEC are not unique and cannot be used for setting them apart from other E. coli strains (54,60-62).
- virulence plasmids of E. coli can be found in other enterobacteria as well (38,48,83,88,89). Because of the diverse serological makeup, identification of pathogenic E. coli by serotyping is also not an accurate means of identification (12,15,28-32).
- Classical colony hybridization assays with probes specific for characteristic virulence factor and/or toxin genes are laborous and timeconsuming (66,67).
- Classical PCR methods require various post-PCR steps in order to verify whether specific amplification of a target gene has occured (68-72).
- the TaqManTM-PCR detection system (74,75,90) enables the rapid, specific, sensitive, and high-throughput diagnosis for differentiation of pathogenic E. coli strains from other strains of E. coli.
- the assay has the ability to quantify the intial target sequence. Since PCR-reaction tubes have not to be opened after PCR cycling, the potential danger of cross-PCR contamination is almost neglegible.
- the scanning time of 96 samples is approximately 8 min, and calculation of test results can be automated with a commercially available spred sheet program. Thus, overall post-PCR processing time is cut to a minimum.
- the TaqManTM-System relies on standard PCR technique with the addition of a specific internal fluorogenic oligonucleotide probe.
- the combination of conventional PCR with the Taq polymerase-dependent degradation of an internally hybridized oligonucleotide probe confers also specificity to this detection method, since it is highly unlikely that unspecific PCR amplification will yield positive fluorescence signals.
- Some rules for chosing the fluorigenic probes have to be obeyed (74,75). Criticial are the length of the probe, the location of reporter and quencher dyes and the absence of a guanosine at the 5′-end (74). Also, the distance of the probe from one of the specific PCR primers is important.
- probes have to stay annealed to the template strand in order to be cleaved by Taq polymerase. Since annealing depends, at least partially, on the T m of the probe, probes should be designed to have a higher T m as the primers. According to the present invention this was solved (except for sltII) by designing probes that were 3 to 6 bp longer than the specific primers. PCR amplification includes extension of the target sequence after annealing of the primers and the T m of the extended primers increases.
- the T m remains constant, making it more likely that the probe dissociates before degradation by Taq polymerase.
- Oligonucleotide probe degradation can be optimized by spatial proximity of the fluorogenic probe and the primer. By moving the probe for sItI from 121 bp to 9 bp close to the primer, a significant improvement in ⁇ RQ values could be obtained.
- a second strategy of optimization of TaqMan-TM-PCR is to perform PCR elongation at 65° C., where it is also less likely that the probe dissociates from the template strand before Taq polymerase reaches and hydrolizes it.
- ⁇ RQ Values for ⁇ RQ can thus again be increased about 1.2 to 1.5 fold.
- the increase of ⁇ RQ values might be due to the ratio of annealed oligonucleotide probe reached by Taq polymerase or to an increased processivity of Taq polymerase.
- the concentration of fluorogenic probes influences the accuracy of TaqManTM-results.
- the probe concentrations were >50 pmol/PCR reaction only a relatively small fraction was hydrolysed by Taq polymerase.
- the ratio of undegraded probe to degraded probe remains high and the fluorescence emmission of the unquenched reporter dye does not significantly increase in relation to the fluorescence intensity of the reporter dye still close to the quencher.
- ⁇ RQ values are lower than with intermediate probe concentrations (10-20 pmol).
- the probe concentration is too low, ⁇ RQ values are increased, however, variability of PCR results is increased, since probably small errors in pipeting or minimal differences between PCR reactions become critical.
- Optimal probe concentration that yielded smallest variabilties and highest RQ values were found at a probe concentration of 20 pmol.
- primers and probes can be amply designed.
- the design of primer and probe sequences is especially important, when nucleotide sequence variants of a given gene exist. This is the case for sltI and sltII.
- sltI all published sequences were aligned and primers and probes were designed to bind to conserved regions of all three variants.
- sltII only one region of the published genes was conserved, thus this region was chosen for the fluorogenic oligonucleotide probe.
- the primers for amplification of sltII were designed to contain all possible nucleotide sequences at the ambiguous positions of the published sltII variants (degenerate primer approach) (79-83). By employing degenerate primers, it is possible to detect all published variants in one single PCR reaction.
- the isolation method for template DNA affects the performance of the PCR. Two methods, that are suited as rapid purification steps for routine applications, namely boiling prep or spin prep were compared. Boiling preps may still contain some bacterial components that can affect PCR reactions, however, it is extremely fast.
- the spin prep method involves isolation steps that serve to purify DNA from potentially negatively influencing materials. ⁇ RQ values and sensitivity of TaqManTM-PCR for virulence genes from enterobacteria was not found significantly increased as compared to boiling preps when template DNA was prepared by spin prep method.
- enterobacteria such as Citrobacter sp. (83) and Enterobacter sp. (89) that can harbor shiga like toxins would be missed in the case of biased enrichment procedures previous to analysis of virulence genes.
- TaqManTM-based PCR that is designed for detection of virulence genes in all enterobacteria appears to be superior.
- the infectious agents of a large proportion of diarrheal diseases is not known. Routine screening for bacterial pathogens in the gastrointestinal tract encompasses Salmonella sp., Shigella sp, S. aureus, Campylobacter sp., Vibrio sp., Yersinia sp., and C. difficile (32). It is well recognized that pathogenic E. coli such as ETEC, EHEC, EIEC, and EaggEC are important pathogens of the lower gastrointestinal tract and therefore might significantly contribute to the number of diarrheal infections (32).
- ETEC EHEC
- EIEC EIEC
- EaggEC are important pathogens of the lower gastrointestinal tract and therefore might significantly contribute to the number of diarrheal infections (32).
- the TaqManTM-assay according to the invention for detection of pathogenic E. coli was then tested in a routine diagnostic setting for the examination of stool samples obtained from children with diarrhea within a defined geographic area (Southern Bavaria) during a 7 month period. Results obtained by TaqManTM-PCR were compared to the standard detection method for PCR products (electrophoresis of ethidium stained agarose gels). 100 stool samples were analysed (Table 4). 22% of samples were found to test positive for one or more virulence factors. There were 2 cases of EHEC, 5 ETEC, 8 EaggEC, 1 EIEC, and 16 EPEC. This means that 1 ⁇ 5 of children with diarrhea probably suffered from diarrhea caused by pathogenic E. coli . These numbers are far higher than these for all other groups of routinely screened bacterial gastrointestinal tract pathogens. Only 2 cases of salmonella and no campylobacter were observed within this group.
- E. coli virulence factor/toxin genes were used as targets for PCR amplification.
- PCR primers and fluorogenic probes were published sequences. Eight different primer and probe sets for detection of pathogenic groups of E. coli and related enterobacteria were specifically chosen, see table 1.
- ETEC Diagnosis of ETEC is based on amplification of either heat labile (LT) (84) or heat stable toxin (ST) (36), EaggEC on pCVD432 plasmid sequences (40,50), EIEC -on inv-plasmid sequences (38,48), EPEC on E. coli attaching and effacing gene (EAF plasmid) (37,85) or E. coli gene for EHEC attaching and effacing protein (eae) (86).
- PCR control amplification for integrity of DNA preparations was performed using primers specific for the E. coli parC gene (topoisomerase IV, Genbank accession M58408) (87).
- TAMRA fluorescent quencher dye
- probe concentration should also have an effect on the assay performance by affecting the fraction of the probe that is degraded during PCR cycling.
- Probe concentrations were titrated in the range of 100 pmol to 0.1 pmol and ⁇ RQ values were determined. Optimal probe concentrations varied in between 10 pmol and 20 pmol depending on the target gene that was amplified.
- EHEC containing either sltl or sltII were diluted in a suspension containing E. coli strain ATCC11775 at 10 7 cfu at log step dilutions. PCR was performed under optimized conditions and results from ethidium-bromide stained agarose gels were compared to TaqManTM results. Minimum detection limits of a sltI containing EHEC strain was 10 3 cfu within 10 7 . For sltII the detection limit was found at 10 3.5 cfu in 10 7 enterobacteria.
- the patient suffering from hemorrhagic colitis tested positive for sltI and eae the patient developing HUS tested positive for sltI, sltII and eae.
- One patient simultaneously harbored ETEC (LT+,ST+), EPEC (eae+), and EaggEC (pCVD342+) one patient tested positive for EIEC (inv+) and EaggEC (pCVD342+)
- Enterobacteria from the two patients with EHEC were hybridized with sltI and sltII gene probes for testing accuracy and specificity of TaqManTM-PCR.
- sltI and sltII gene probes for testing accuracy and specificity of TaqManTM-PCR.
- Colonies of patient two, where TaqManTM-PCR was positive for sltI and sltII hybridized with probes for sltI and sltII. Positive colonies were picked and biochemically typed as E. coli.
- EHEC strains were sensitive to broad spectrum penicillins, cephalosporins and gyrase inhibitors.
- E. coli ATCC 11775 was used as a strain not harboring these virulence genes.
- E. coli ATCC 11775 was used as a strain not harboring these virulence genes.
- positive control strains were grown on McConkey agar (Becton Dickinson, Germany) at 37° C. After overnight culture, bacteria were collected and resuspended in 0.9% NaCl solution. Turbidity was adjusted to McFarland 0.5.
- DNA was either prepared by boiling (95° C., 10 min) or isolated using QiaAmp tissue kit spin prep columns (Qiagen, Germany). 10 ⁇ l of DNA suspension was used for PCR. Detection of pathogenic E. coli strains from stool specimen of humans or cows was performed after spreading an appropriate amount of stool on McConkey plates. After overnight culture all bacterial colonies from the surface of the McConkey plates were collected and processed as detailed above.
- PCR-cyling PCR recations were set up in 70 ⁇ l final volume in thin-walled 0.2 ml “optical PCR-tubes” (Perkin Elmer, Germany). The reaction mix contained: 10 ⁇ l of bacterial lysate, 5.25 ⁇ l 25 mmol MgCl 2 , 7 ⁇ l 10 ⁇ PCR buffer, 40 pmol primers, 20 pmol specific fluorogenic probe, 150 ⁇ M of each dATP, dTTP, dGTP, dCTP (Perkin Elmer), 1 U AmpliTaq-Polymerase (Perkin Elmer). A Perkin Elmer model 9600 thermal cycler was used for PCR cycling.
- PCR products were subjected to agarose gel electrophoresis. 15 ⁇ l of sample were loaded with 2 ⁇ l sample buffer. PCR products were separated in 2% agarose gels containing ethidium bromide at 100V for 35 min. DNA was visualized under UV light and a digital image file was obtained using the Eagle EyeII System (Stratagene).
- PCR product obtained from templates of respective positive control strains were directly subcloned into the TA cloning vector (Invitrogen, Germany) for verification of specificity of PCR amplification.
- TA cloning vector Invitrogen, Germany
- plasmid containing bacteria were selected on ampicillin (Sigma, Germany) containing LB plates. Plasmid DNA was purified with Qiagen DNA purification columns (Quiagen, Germany). Inserts were PCR-cycle sequenced employing dideoxy-nucleotides conjugated to 4 dyes (DNA Dye terminator cycle sequencing kit, Perkin Elmer, Germany).
- EHEC bacterial strains and stool samples from patients testing positive in sltI or sltII TaqManTM-PCR were subjected to colony hybridisation. Briefly, bacteria were plated on McConkey agar plates such that single colonies could be seen. Bacteria were blotted on nylon membranes (Genescreen Plus, NEN, Germany), cracked (1% SDS), denatured (0.5M NaOH, 1.5M NaCl), neutralized (1M TRIS, 1.5M NaCl), and washed (20 ⁇ SSC). Membranes were baked at 80° C. for 2 hours.
- DNA probes specific for sltI or sltII were labelled with fluorescein (Gene-Images random prime labelling module, Amersham, Germany). Afterwards, filters were hybridized with labelled probes. Hybridization was verified by non-radioactive detection system employing anti-FITC peroxidase mAb and ECL detection module (Gene-Images CDP-Star detection module, Amersham, Germany). Bacterial colonies hybridizing with the probe and non-hybridizing colonies were picked, verified by TaqMan-PCR and tested for antibiotic susceptibility. Antibiotic susceptibility testing. EHEC and non-EHEC E.
- ETEC LT LT-1 gcg tta cta tcc tct 874-895 339 S60731 (84) cta tgt g LT-2 agt ttt cca tac tga 1213-1192 ttg ccg c ST ST-1 tcc ctc agg atg cta 100-120 260 M34916 (36) aac cag ST-2a tcg att tat tca aca 360-339 aag caa c EaggEC pCVD432 EA-1 ctg gcg aaa gac 66-87 629 X81423 (40, 50) plasmid tgt atc att g EA-2 taa tgt ata gaa atc 695-674 cgc tgt t EIEC inv- EI-1 ttt ctg gat
- ETEC LT agc tcc cca gtc tat tac aga act atg 903-929 S60731 (84) ST aca tac gtt aca gac ata atc aga atc ag 334-306 M34916 (36) EaggEC pCVD432 ctc ttt taa ctt atg ata tgt aat gtc tgg 668-639 X81423 (40, 50) plasmid EIEC inv- caa aaa cag aag aac cta tgt cta cct 18063-18037 D50601 (38, 48) plasmid emb EPEC EAF- ctt gga gtg atc gaa cgg gat cca aat 575-601 X76137 (37, 85) plasmid eae taa acg ggt at
- H7 antiserum-sorbitol fermentation medium a single tube screening medium for detecting Escherichia coli O157:H7 associated with hemorrhagic colitis. J. Clin. Microbiol. 22:620.
- Enteroaggregative Escherichia coli heat-stable enterotoxin 1 represents another subfamily of E. coli heat-stable toxin. Proc. Natl. Acad. Sci. U.S.A. 90:3093.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates to a method for the detection of pathogenic E. coli in a sample comprising PCR amplification of DNA isolated from said sample using oligonucleotide primers specific for pathogenic E. coli.
Description
- The present invention relates to a rapid, high performance assay for the detection of pathogenicE. coli which is based on TaqMan™PCR technique, and to specific optimised oligonucleotide primers and labelled oligonucleotide probes useful in the assay.
- Enterohemorrhagic, shiga-like toxin (sit) producingEscherichia coli (EHEC) have recently been recognized as an important human and animal pathogen (1-7). EHEC has been responsible for several food-borne outbreaks (8). The most notable were a multistate outbreak associated with a fast food chain in the western states of the USA with more than 600 individuals affected and 3 deaths in Washington (9), and an epedemic occurence in Japan with more than 6000 patients and approx. 8 fatal cases (10). Infection with EHEC causes diarrhea, hemorrhagic colitis, thrombotic thrombocytopenic purpura, and hemolytic uremic syndrome (HUS) that is characterised by acute renal failure, thrombocytopenia, and microangiopathic hemolytic anemia. HUS ultimately can result in a fatal outcome in affected children and immunocompromised individuals (3,11-17). Recently, in the South-Eastern parts of Germany (Bavaria) an increase of EHEC cases was reported during October 1995 and July 1996 with at least 45 severe infections leading to HUS accompanied by 7 deaths (18). Estimating that approx. 1 out of 15 EHEC infections results in HUS approx. 600-700 affected individuals might be assumed.
- In most outbreaks reported, consumption of contaminated ground beef has been the source of infection (5,8,19-22), whereas in Japan raddish sprouts are suspected (10). EHEC has been isolated from cow milk (6,19,23), Water (19), chicken, pork, and apple cider (19,24,25), but also human horizontal smear infections have been reported (15). Cattle appear likely to be the reservoir (22,26). Cross contamination, improper handling, and inadequate cooking all contribute to food-borne infections caused by EHEC. EHEC produce Shiga-like toxins (sit), also known as verotoxins or cytotoxins (12,27). A large proportion of EHEC have been found to belong to the serogroup O157:H7, but notably, also a variety of EHEC belonging to other serogroups (O22, O26, O55, O111, O114, O145) have been reported especially in Europe (12,15,28-32).
- Besides EHEC, certain other strains ofE. coli can cause enteritis or gastroenteritis and are grouped in enterotoxigenic strains (ETEC) (33-36), enteropathogenic strains (EPEC) (37), enteroinvasive strains (EIEC) (38,39), and enteroaggregative strains (EaggEC) (40,41). These strains are important pathogens and also pose severe public health problems. The diagnosis of these pathogens is vastly neglegted due to the lack of specific and sensitive routine test methods. ETEC synthesize heat labile and/or heat stable enterotoxins that can cause a secretory diarrhea (“traveller's diarrhea”) resembling that of Vibrio cholerae (36,42,43). Surface attachment of the ETEC organisms to the intestinal epithelial cell is a prerequisite to toxin production. Toxin production is plasmid mediated and most commonly involves E. coli serogroups O6, O15, O124, O136, O143, O145, and 0147 (32).
- EPEC cause diarrheal symptoms primarily in infants (32). Although the pathogenesis is unclear, the epithelial degradation of the gut, and the inflammatory response that are observed in tissue sections may be a consequence due to the adhesive properties of the bacterium. Specific attachment factors of EPEC are plasmid encoded (EAF=EPEC adherence factor) (37,44). EHEC often contain an adherence factor closely related to EAF that is known as eae (EHEC attaching and effacing gene) (45,46). EPEC most often belong to serogroups O6, O8, O25, O111, O119, and O142 (32).
- EIEC strains are capable of penetrating and invading the intestinal epithelial cells and produce an inflammatory diarrhea similar to that caused by Shigella bacteria (38,47,48). Fecal smears contain blood, mucus and segmented neutrophils. EIEC contain virulence plasmids coding for additional pathogenic factors (48). Serogroups O28, O112, O115, O124, O136, O143, O145, and O147 are most commonly found on EIEC (32).
- EaggEC are associated with persistent diarrhea in children and with traveller's diarrhea. EaggEC are characterized by their adherence capacity that leads to aggregation of Hep-2 cells. This effect is associated with the presence of a virulence plasmid (pCVD432). EaggEC are supected to also produce a heat stable enterotoxin (EAST1) (49-53). They can belong to serogroups O44 and O126 (32).
- Conventional detection methods for EHEC encompass enrichment and isolation with selective and/or indicator media such asE. coli broth, lauryl sulfate tryptose 4-methylumbelliferyl-b-acid broth, eosin methylene blue agar, McConkey sorbitol agar, and enterohemolysin agar (28,32,54-59). All of these assays, unfortunately, are indirect and lack the ability to identify EHEC or the other pathogenic E. coli strains specifically. Several methods for biochemical identification and immunological detection of EHEC have been put forward (54,60-63), however, it is well recognized that pathogenic E. coli strains neither posess nor lack unique fermentation pathways (58,64). Serotyping is not conclusive since no absolute correlation between serotype and pathogenic E. coli group can be established (12,27,32,58,65).
- DNA hybridization techniques have been established for experimental research but are not applicable for large scale routine diagnostic procedures (66,67). DNA amplification based assays, using PCR have been reported (68-72). Limitations to these methods include cumbersome post-PCR detection methods (agarose gel electrophoresis, Biotin/Avidin based ELISA detection systems).
- To overcome these problems, a PCR assay which allows the specific determination of virulence factors characteristic for EHEC, ETEC, EPEC, EIEC, and EaggEC that is based on a fluorigenic detection method of PCR amplification has been developed.
- This assay exploits the 5′→3′exonuclease activity of Taq-DNA polymerase (73) to cleave an internal oligonucleotide probe that is covalently conjugated- with a fluorescent reporter dye (e.g. 6-carboxy-fluorescein [FAM]; λem=518 nm) and a fluorescent quencher dye (6-carboxytetramethyl-rhodamine [TAMRA]; λem=582 nm) at the 5′ and 3′end, respectively (74,75). Fluorescence from FAM is efficiently quenched by TAMRA on the same, intact probe molecule (76). In the case that cognate PCR amplification occurs, Taq polymerase extends from the specific PCR primer and cleaves the internal, fluorigenic oligonucleotide probe annealed to the template strand. Thus, the reporter dye and the quencher dye get spatially separated. As a consequence of oligonucleotide hydrolysis and physical separation of the reporter and the quencher dyes, a measurable increase in fluoresecence intensity at 518 nm can be observed. PCR cycling leads to exponential amplification of the PCR product and consequently of fluorescence intensity.
- TaqMan™-PCR is performed in optical tubes that allow measurements of fluorescence signals without opening the PCR tubes. This dramatically minimizes post-PCR processing time and almost completely eliminates cross-PCR contamination problems. Employing this approach, simultaneous testing of biological materials for the presence of virulence genes ofE. coli strains and other enterobacteria, harboring virulence genes can be semiautomated and performed within 18 h.
- According to the present invention TaqMan™-PCR for the detection of pathogenicE. coli is provided, enabling for the first time the specific, rapid and high throughput routine detection of EHEC, ETEC, EFEC, EIEC, and EaggEC and related enterobacteria that harbor these virulence genes in routine bacteriological laboratories.
- It is an object of the present invention to provide a rapid, high performance assay for the detection and identification of pathogenicE. coli in biological samples.
- It is a further object of the present invention to provide specific, optimised primers and labelled oligonucleotide probes useful for the amplification of sequences encoding virulence factors/toxins characteristic for pathogenicE. coli
- The invention then, inter alia, comprises the following alone or in combination:
- A method for the detection of pathogenicE. coli in a sample comprising PCR amplification of DNA isolated from said sample using a set of oligonucleotide primers specific for virulence factors/toxins of pathogenic E. coli selected from
- primers that hybridise to a gene encoding heat labile toxin, or heat stabile toxin for the amplification of a DNA sequence characteristic for enterotoxigenicE. coli;
- primers that hybridise to a gene encoding heat stabile toxin for the amplification of a DNA sequence characteristic for enteroaggregativeE. coli;
- primers that hybridise to the pCVD432 plasmid for the amplification of a DNA sequence characteristic for enteroaggregativeE. coli;
- primers that hybridise to the inv-plasmid for the amplification of a DNA sequence contained in enteroinvasiveE. coli;
- primers that hybridise to the EAF plasmid, or the eae gene for the amplification of a DNA sequence characteristic for enteropathogenicE. coli; and/or
- primers that hybridise to the genes encoding shiga-like toxin sltI or sltII for the amplification of a DNA sequence characteristic for enterohemorrhagicE. coli, followed by detection and identification of the amplified product using conventional methods;
- the method as above wherein
- the set of primers that hybridise to the gene encoding heat labile toxin characteristic for enterotoxigenicE. coli is
LT-1: 5′ GCG TTA CTA TCC TCT CTA TGT G 3′ and LT-2: 5′ AGT TTT CCA TAC TGA TTG CCG C 3′; - the set of primers that hybridise to the gene encoding heat stabile toxin characteristic for enterotoxigenicE. coli is
ST-1: 5′ TCC CTC AGG ATG CTA AAC CAG 3′ and ST-2a: 5′ TCG ATT TAT TCA ACA AAG CAA C 3′; - the set of primers that hybridise for the gene encoding heat stabile toxin characteristic for enteroaggregativeE. coli is
EASTI-1: 5′ AAC TGC TGG GTA TGT GGC TGG 3′ and EASTI-2: 5′ TGC TGA CCT GCC TCT TCC ATG 3′; - the set of primers which hybridise to the pCVD432 plasmid is
EA-1: 5′ CTG GCG AAA GAC TGT ATC ATT G 3′ and EA-2: 5′ TAA TGT ATA GAA ATC CGC TGT T 3′; - the set of primers which hybridise to the inv-plasmid is
EI-1: 5′ TTT CTG GAT GGT ATG GTG AGG 3′ and EI-2: 5′ CTT GAA CAT AAG GAA ATA AAC 3′; - the set of primers which hybridise to the EAF plasmid is
EP-1: 5′ CAG GGT AAA AGA AAG ATG ATA AG 3′ and EP-2: 5′ AAT ATG GGG ACC ATG TAT TAT C 3′; - the set of primers which hybridise to the eae gene is
EPeh-1: 5′ CCC GGA CCC GGC ACA AGC ATA AG 3′ and EPeh-2: 5′ AGT CTC GCC AGT ATT CGC CAC C 3′; - the primers which hybridises to the gene encoding shiga-like toxin SltI is
SltI-1: 5′ ATG AAA AAA ACA TTA TTA ATA GC 3′ and SltI-2: 5′ TCA CYG AGC TAT TCT GAG TCA AGC 3′; and - the primers which hybridises to the gene encoding shiga-like toxin SltII is
SltII-1: 5′ ATG AAG AAG ATR WTT RTD GCR GYT TTA TTY G 3′ and SltII-2: 5′ TCA GTC ATW ATT AAA CTK CAC YTS RGC AAA KCC 3′ - wherein W is A/T, R is A/G, D is A/G/T, Y is C/T and K is G/T;
- the method as above wherein a polymerase having additional 5′-3′ exonuclease activity is used for the amplification of DNA, and an oligonucleotide probe labelled at the most 5′ base with a fluorescent dye and at the most 3′ base with a fluorescent quencher dye which hybridises within the target DNA is included in the amplification process; said labelled oligonucleotide probe being susceptible to 5′-3′ exonuclease degradation by said polymerase to produce fragments that can be detected by fluorogenic detection methods;
- the method as above wherein
- the labelled oligonucleotide probe for the detection of heat labile toxin characteristic for enterotoxigenicE. coli is
- 5′ AGC TCC CCA GTC TAT TAC AGA ACT ATG 3′;
- the labelled oligonucleotide probe for the detection of heat stabile toxin characteristic for enterotoxigenicE. coli is
- 5′ ACA TAC GTT ACA GAC ATA ATC AGA ATC AG 3′;
- the labelled oligonucleotide probe for the detection of heat stabile toxin characteristic for enteroaggregativeE. coli is
- 5′ ATG AAG GGG CGA AGT TCT GGC TCA ATG TGC 3′;
- the labelled oligonucleotide probe for the detection of pCVD432 plasmid is
- 5′ CTC TTT TAA CTT ATG ATA TGT AAT GTC TGG 3′;
- the labelled oligonucleotide probe for the detection of the inv-plasmid is;
- 5′ CAA AAA CAG AAG AAC CTA TGT CTA CCT 3′
- the labelled oligonucleotide probe for the detection of the EAF-plasmid is;
- 5′ CTT GGA GTG ATC GAA CGG GAT CCA AAT 3′;
- the labelled oligonucleotide probe for the detection of the eae gene is
- 5′0 TAA ACG GGT ATT ATC AAC AGA AAA ATC C 3′;
- the labelled oligonucleotide probe for the detection of shiga-like toxin SltI gene is
- 5′ TCG CTG AAT CCC CCT CCA TTA TGA CAG GCA 3′; and
- the labelled oligonucleotide probe for the detection of shiga-like toxin SltII gene is
- 5′ CAG GTA CTG GAT TTG ATT GTG ACA GTC ATT 3′;
- the method as above wherein the fluoroscent reporter dye is 6-carboxy- fluoroscein, tetrachloro-6-carboxy-fluoroscein, or hexachloro-6-carboxy- fluoroscein, and the fluorescent quencher dye is 6-carboxytetramethyl- rhodamine;
- the method as above wherein the PCR amplification process consists of 35 PCR cycles at a MgCl2 concentration of 5.2 mmol, an annealing temperature of 55° C. and an extension temperature of 65° C.;
- a set of primers useful for PCR amplification of DNA specific for virulence factors/toxins of pathogenicE. coli selected from:
- a set of primers that hybridise to a gene encoding heat labile toxin, or heat stabile toxin of enterotoxigenicE. coli;
- a set of primers that hybridise to a gene encoding heat stabile toxin of enteroaggregativeE. coli;
- a set of primers that hybridise to the pCVD432 plasmid of enteroaggregativeE. coli;
- a set of primers that hybridise to the inv-plasmid of enteroinvasiveE. coli;
- a set of primers that hybridise to the EAF plasmid, or the eae gene of enteropathogenicE. coli; and
- a set of primers that hybridise to the gene encoding shiga-like toxin sltI or sltI of enterohemorrhagicE. coli;
- the set of primers as above wherein
- the set of primers which hybridise to the gene encoding heat labile toxin of enterotoxigenicE. coli is
LT-1: 5′ GCG TTA CTA TCC TCT CTA TGT G 3 and LT-2: 5′ AGT TTT CCA TAC TGA TTG CCG C 3′; - the set of primers which hybridise to the gene encoding heat stabile toxin of enterotoxigenicE. coli is
ST-1: 5′ TCC CTC AGG ATG CTA AAC CAG 3′ and ST-2a: 5′ TCG ATT TAT TCA ACA AAG CAA C 3′;. - the set of primers which hybridise to the gene encoding heat stabile toxin of enteroaggregativeE. coli is
EASTI-1: 5′ AAC TGC TGG GTA TGT GGC TGG 3′ and EASTI-2: 5′ TGC TGA CCT GCC TCT TCC ATG 3′; - the set of primers which hybridise to the pCVD432 plasmid is
EA-1: 5′ CTG GCG AAA GAC TGT ATC ATT G 3′ and EA-2: 5′ TAA TGT ATA GAA ATC CGC TGT T 3′; - the set of primers which hybridise to the inv-plasmid is
EI-1: 5′ TTT CTG GAT GGT ATG GTG AGG 3′ and EI-2: 5′ CTT GAA CAT AAG GAA ATA AAC 3′; - the set of primers which hybridise to the EAF plasmid is
EP-1: 5′ CAG GGT AAA AGA AAG ATG ATA AG 3′ and EP-2: 5′ AAT ATG GGG ACC ATG TAT TAT C 3′; - the set of primers which hybridise to the eae gene is
EPeh-1: 5′ CCC GGA CCC GGC ACA AGC ATA AG 3′ and EPeh-2: 5′ AGT CTC GCC AGT ATT CGC CAC C 3′; - the set of primers which hybridise to the shiga-like toxin sltI gene is
SltI-1: 5′ ATG AAA AAA ACA TTA TTA ATA GC 3′ and SltI-2: 5′ TCA CYG AGC TAT TCT GAG TCA AGC 3′; - and
- the set of primers which hybridise to the shiga-like toxin sltII is
SltII-1: 5′ ATG AAG AAG ATR WTT RTD GCR GYT TTA TTY G 3′ and SltII-2: 5′ TCA GTC ATW ATT AAA CTK CAC YTS RGC AAA KCC 3′ - wherein W is A/T, R is A/G, D is A/G/T, Y is C/T and K is G/T; the set of primers as above which in addition to the primers for amplification of target DNA comprise a labelled oligonucleotide probe which is labelled with a fluoroscent reporter dye, such as 6-carboxy-fluoroscein, tetrachloro-6-carboxy-fluoroscein, hexachloro-6-carboxy-fluoroscein, at the most 5′ base and a fluoroscent quencher dye, such as 6-carboxytetramethyl-rhodamine, at the most 3′ base, and have a nucleotide sequence selected from
- 5′ AGC TCC CCA GTC TAT TAC AGA ACT ATG 3′
- which hybridises to a gene encoding heat labile toxin of enterotoxigenicE. coli;
- 5′ ACA TAC GTT ACA GAC ATA ATC AGA ATC AG 3′
- which hybridises to a gene encoding heat stabile toxin of enterotoxigenicE. coli;
- 5′ ATG AAG GGG CGA AGT TCT GGC TCA ATG TGC 3′
- which hybridises to a gene encoding heat stabile toxin of enteroaggregativeE. coli;
- 5′ CTC TTT TAA CTT ATG ATA TGT AAT GTC TGG 3′
- which hybridises to the pCVD432 plasmid;
- 5′CAA AAA CAG AAG AAC CTA TGT CTA CCT 3′
- which hybridises to the inv-plasmid;
- 5′ CTT GGA GTG ATC GAA CGG GAT CCA AAT 3′
- which hybridises to the EAF plasmid;
- 5′ TAA ACG GGT ATT ATC AAC AGA AAA ATC C 3′
- which hybridises to the eae gene;
- 5′ TCG CTG AAT CCC CCT CCA TTA TGA CAG GCA 3′
- which hybridises to the shiga-like toxin SltI gene; and
- 5′ CAG GTA CTG GAT TTG ATT GTG ACA CTC ATT 3′
- which hybridises to the shiga-like toxin SltII gene; the use of the method as above for diagnosing anE. coli infection of a living animal body, including a human, or for the detection of E. coli contamination of consumables, such as meat, milk and vegetables.
- Conventional methods used to detect PCR amplification are laboursome, employ potentially carcinogenic substances (ethidium bromide gel electrophoresis), and are not suited as a routine assay method in the microbiological routine laboratory (68-72). This poses a serious problem, especially when potential pathogenic bacteria cannot be differentiated from facultative pathogenic or apathogenic ones due to characteristic biochemical, serological and/ or morphological criteria. Thus, specific nucleic acid-based diagnostic methods that directly detect virulence factors or toxins harbored by these species are mandatory. This is in principal the case for the diagnosis of pathogenicE. coli bacteria. Biochemical properties of EHEC, EPEC, EIEC, ETEC, and EaggEC are not unique and cannot be used for setting them apart from other E. coli strains (54,60-62). Furthermore, virulence plasmids of E. coli can be found in other enterobacteria as well (38,48,83,88,89). Because of the diverse serological makeup, identification of pathogenic E. coli by serotyping is also not an accurate means of identification (12,15,28-32). Classical colony hybridization assays with probes specific for characteristic virulence factor and/or toxin genes are laborous and timeconsuming (66,67). Classical PCR methods require various post-PCR steps in order to verify whether specific amplification of a target gene has occured (68-72). The TaqMan™-PCR detection system (74,75,90) enables the rapid, specific, sensitive, and high-throughput diagnosis for differentiation of pathogenic E. coli strains from other strains of E. coli. The assay has the ability to quantify the intial target sequence. Since PCR-reaction tubes have not to be opened after PCR cycling, the potential danger of cross-PCR contamination is almost neglegible. The scanning time of 96 samples is approximately 8 min, and calculation of test results can be automated with a commercially available spred sheet program. Thus, overall post-PCR processing time is cut to a minimum.
- The TaqMan™-System relies on standard PCR technique with the addition of a specific internal fluorogenic oligonucleotide probe. The combination of conventional PCR with the Taq polymerase-dependent degradation of an internally hybridized oligonucleotide probe confers also specificity to this detection method, since it is highly unlikely that unspecific PCR amplification will yield positive fluorescence signals. Some rules for chosing the fluorigenic probes have to be obeyed (74,75). Criticial are the length of the probe, the location of reporter and quencher dyes and the absence of a guanosine at the 5′-end (74). Also, the distance of the probe from one of the specific PCR primers is important. This is due to the fact that the probe has to stay annealed to the template strand in order to be cleaved by Taq polymerase. Since annealing depends, at least partially, on the Tm of the probe, probes should be designed to have a higher Tm as the primers. According to the present invention this was solved (except for sltII) by designing probes that were 3 to 6 bp longer than the specific primers. PCR amplification includes extension of the target sequence after annealing of the primers and the Tm of the extended primers increases. For the fluorogenic oligonucleotide probe, where the 3′-end is capped in order to avoid elongation, the Tm remains constant, making it more likely that the probe dissociates before degradation by Taq polymerase. Oligonucleotide probe degradation can be optimized by spatial proximity of the fluorogenic probe and the primer. By moving the probe for sItI from 121 bp to 9 bp close to the primer, a significant improvement in ΔRQ values could be obtained. A second strategy of optimization of TaqMan-™-PCR is to perform PCR elongation at 65° C., where it is also less likely that the probe dissociates from the template strand before Taq polymerase reaches and hydrolizes it. Values for ΔRQ can thus again be increased about 1.2 to 1.5 fold. The increase of ΔRQ values might be due to the ratio of annealed oligonucleotide probe reached by Taq polymerase or to an increased processivity of Taq polymerase.
- The concentration of fluorogenic probes influences the accuracy of TaqMan™-results. When the probe concentrations were >50 pmol/PCR reaction only a relatively small fraction was hydrolysed by Taq polymerase. The ratio of undegraded probe to degraded probe remains high and the fluorescence emmission of the unquenched reporter dye does not significantly increase in relation to the fluorescence intensity of the reporter dye still close to the quencher. Thus, at high probe concentrations, ΔRQ values are lower than with intermediate probe concentrations (10-20 pmol). When the probe concentration is too low, ΔRQ values are increased, however, variability of PCR results is increased, since probably small errors in pipeting or minimal differences between PCR reactions become critical. Optimal probe concentration that yielded smallest variabilties and highest RQ values were found at a probe concentration of 20 pmol.
- Since TaqMan™-PCR uses an internal oligonucleotide probe for detection of template amplification, specific primers and probes can be amply designed. The design of primer and probe sequences is especially important, when nucleotide sequence variants of a given gene exist. This is the case for sltI and sltII. For sltI, all published sequences were aligned and primers and probes were designed to bind to conserved regions of all three variants. For sltII, only one region of the published genes was conserved, thus this region was chosen for the fluorogenic oligonucleotide probe. The primers for amplification of sltII were designed to contain all possible nucleotide sequences at the ambiguous positions of the published sltII variants (degenerate primer approach) (79-83). By employing degenerate primers, it is possible to detect all published variants in one single PCR reaction.
- The isolation method for template DNA affects the performance of the PCR. Two methods, that are suited as rapid purification steps for routine applications, namely boiling prep or spin prep were compared. Boiling preps may still contain some bacterial components that can affect PCR reactions, however, it is extremely fast. The spin prep method involves isolation steps that serve to purify DNA from potentially negatively influencing materials. ΔRQ values and sensitivity of TaqMan™-PCR for virulence genes from enterobacteria was not found significantly increased as compared to boiling preps when template DNA was prepared by spin prep method.
- The overall sensitivity of TaqMan-PCR for all primer/probe combinations was comparable to visual scoring of PCR products by detection with ethidium bromide stained agarose gel electrophoresis. Under optimized conditions, as few as 103 cfu sitI+ EHEC could be detected among 107 non-pathogenic E. coli per PCR reaction.
- The use of immunomagnetic detection methods forE. coli O157 (54,91) has been put forward as a means to improve sensitivity of EHEC diagnostics by enrichment of this serogroup since the first slt producing strains were found to be O157:H7 positive (1,2). However, it is obvious that EHEC that are O157 antigen negative will be missed by this method. It became clear during serotyping studies of recent EHEC isolates that the number of O157+ EHEC now is small as compared to non-O157 EHEC (12,15,28,29,31). In a recent study, conducted in Southern Germany only 2 of 13 isolates were O157 positive (92). Immunomagnetic detection methods for other O serotypes are currently not available. Also, other enterobacteria such as Citrobacter sp. (83) and Enterobacter sp. (89) that can harbor shiga like toxins would be missed in the case of biased enrichment procedures previous to analysis of virulence genes. Thus, TaqMan™-based PCR that is designed for detection of virulence genes in all enterobacteria appears to be superior.
- The infectious agents of a large proportion of diarrheal diseases is not known. Routine screening for bacterial pathogens in the gastrointestinal tract encompasses Salmonella sp., Shigella sp,S. aureus, Campylobacter sp., Vibrio sp., Yersinia sp., and C. difficile (32). It is well recognized that pathogenic E. coli such as ETEC, EHEC, EIEC, and EaggEC are important pathogens of the lower gastrointestinal tract and therefore might significantly contribute to the number of diarrheal infections (32). However, no routine bacteriological diagnostic procedures for these bacteria are performed, and, moreover, in most cases these pathogenic E, coli are misdiagnosed under the category of non-pathogenic “commensal flora”. in order to address this problem a set of specific primers and fluorogenic probes were developed and optimized for TaqMan-™-based detection of virulence factors harbored by these bacteria (Tables 2 and 3). Arranging patient samples, positive and no-template controls of all 8 tested virulence genes in a standard 96 well microtiter format, a turnaround time from preparation of sample DNA to fluorescence measurement of under 5 hours can be achieved. Thus, the TaqMan™-based assay for pathogenic E. coli provides an ultrarapid means of diagnosis of these bacteria. While being accurate, sensitive and specific, this assay requires minimal post-PCR processing time compared to conventional methods. When TaqMan-™ PCR is performed in optical tubes also the danger of cross-contamination of PCR reactions with amplified products is reduced to a minimum. Detection of virulence plasmids harbored by pathogenic enterobacteria might prove the potential of these bacteria to cause disease in the host. It is not clear whether enterobacteria that contain toxin genes or attachment factors do also always express them outside the host. This might be an explanation why ELISA tests for shiga like toxins might be negative in a number of HUS cases where sltI and/or sltII containing EHECs can be detected by nucleic acid based methods.
- The TaqMan™-assay according to the invention for detection of pathogenicE. coli was then tested in a routine diagnostic setting for the examination of stool samples obtained from children with diarrhea within a defined geographic area (Southern Bavaria) during a 7 month period. Results obtained by TaqMan™-PCR were compared to the standard detection method for PCR products (electrophoresis of ethidium stained agarose gels). 100 stool samples were analysed (Table 4). 22% of samples were found to test positive for one or more virulence factors. There were 2 cases of EHEC, 5 ETEC, 8 EaggEC, 1 EIEC, and 16 EPEC. This means that ⅕ of children with diarrhea probably suffered from diarrhea caused by pathogenic E. coli. These numbers are far higher than these for all other groups of routinely screened bacterial gastrointestinal tract pathogens. Only 2 cases of salmonella and no campylobacter were observed within this group.
- Interestingly, the two children diagnosed with EHEC were severely sick, one suffered from hemorrhagic colitis, the other developed HUS and had to be treated in a critical care unit.
- Collectively, these investigations show that a large proportion of diarrheal diseases in children and also in adults are associated with pathogenicE. coli that are falsely diagnosed as commensal flora in standard microbiological procedures. The TaqMan™-methodology according to the invention for the first time enables the direct, fast, specific, and sensitive detection of these important pathogens. Moreover, virulence genes detected with this approach are not confined to E. coli, they also can be freely transmitted to other enterobacteria. Detection of the virulence genes within these bacteria would also be covered by the herein described TaqMan™-PCR. The assay requires only minimal post-PCR detection time, can thus be performed under 18 hours, and abolishes PCR-cross contamination problems.
- According to the present inventionE. coli virulence factor/toxin genes were used as targets for PCR amplification. PCR primers and fluorogenic probes were published sequences. Eight different primer and probe sets for detection of pathogenic groups of E. coli and related enterobacteria were specifically chosen, see table 1.
- Primer sequences and their locations with GenBank accessions are detailed in Table 2. Detection of EHEC sltl is based on consensus primer and probe sequences after alignment of sltI homologous genes (Genbank accessions Z36899, Z36900, and Z36901) (77,78). Detection of sltII variants is based on published sequences of homologous genes (Genbank accessions M76738, Z37725, L11079, X67515, M59432, M29153, M36727, and M21534) (79-83). For amplification of sltII, degenerate primer sets proved optimal. Diagnosis of ETEC is based on amplification of either heat labile (LT) (84) or heat stable toxin (ST) (36), EaggEC on pCVD432 plasmid sequences (40,50), EIEC -on inv-plasmid sequences (38,48), EPEC onE. coli attaching and effacing gene (EAF plasmid) (37,85) or E. coli gene for EHEC attaching and effacing protein (eae) (86). PCR control amplification for integrity of DNA preparations was performed using primers specific for the E. coli parC gene (topoisomerase IV, Genbank accession M58408) (87).
- Oligonucleotide probes and their Genbank Ref. are shown in table 3. Oligonucleotide probes were designed (if possible) with a GC-content of 40-60%, no G-nucleotide at the 5′-end, length of probes was 27 to 30 bp. Probes were covalently conjugated with a fluorescent reporter dye (e.g. 6-carboxy-fluorescein [FAM]; λem=518 nm) and a fluorescent quencher dye (6-carboxytetram-ethyl-rhodamine [TAMRA]; λem=582 nm) at the most 5′ and most 3′ base, respectively. All primers and probes were obtained from Perkin Elmer, Germany.
- TaqMan™-PCR was optimized by isolation of DNA fromE. coli control strains harboring genes for LT, ST, inv-plasmid, pCVD342, EAF, eae, sltI and sltII (see Table 1). MgCl2 concentrations were adjusted for maximum PCR product yields (as verified by agarose gel electrophoresis) and RQ values (RQ=FAMfluorescence intensity/TAMRAfluorescence intensity) with the above mentioned pathogenic E. coli control strains. Optimum PCR reactions for all primer/fluorigenic probes used were obtained at a MgCl2 concentration of 5.2 mmol, 35 PCR cycles, an annealing temperature of 55° C. and an extension temperature of 65° C. Extension at 65° C. was found to yield higher RQ values, probably due to a lower rate of template/fluorogenic probe dissociation before degradation by Taq-polymerase.
- TheE. coli sltl gene was used as a target sequence for establishment of PCR and analysing different locations of probes relative to the PCR primers. Primers were designed to anneal in conserved regions of the sltI genes (see above). Two probes, sltI-NO located 132 bp upstream of one primer and sltI-N1, placed at a 21 bp distance from the primer were compared. RQ values achieved with probe sltI-N1(RQm=6.3800) were reproducably found higher than RQ values generated with probe sltI-NO (RQm=0.9620) at equal template concentrations of the E. coli sltI control DNA. Generally, also probes specific for other target genes that were located close (4 to 20 bp) to one of the two PCR primers yielded consistently higher RQ values than probes that were placed at a greater distance from the primers.
- The influence of DNA preparation on the performance of TaqMan™-PCR was tested, since it has been reported that crude bacterial lysates can contain inhibiting factors that might interfere with PCR performance. Therefore, bacteria were collected after overnight growth on McConkey plates. DNA was prepared by boiling of bacteria inoculated in 0.9% NaCl solution or by isolation of genomic DNA with a commercial spin prep procedure (see the example, material and methods). The RQ values and sensititvity of TaqMan™-PCR did not differ when the two preparation methods were compared. The RQ values obtained for PCR amplifications from DNA derived from 105 sltI or sltII containing EHEC prepared by boiling or by spin prep comparable.
- The TaqMan™-PCR method relies on the detection of free reporter dye (FAM) that is released from the probe after hydrolysis. Thus, probe concentration should also have an effect on the assay performance by affecting the fraction of the probe that is degraded during PCR cycling. Probe concentrations were titrated in the range of 100 pmol to 0.1 pmol and ΔRQ values were determined. Optimal probe concentrations varied in between 10 pmol and 20 pmol depending on the target gene that was amplified.
- For testing sensitivity of TaqMan-PCR, EHEC containing either sltl or sltII were diluted in a suspension containingE. coli strain ATCC11775 at 107 cfu at log step dilutions. PCR was performed under optimized conditions and results from ethidium-bromide stained agarose gels were compared to TaqMan™ results. Minimum detection limits of a sltI containing EHEC strain was 103 cfu within 107. For sltII the detection limit was found at 103.5 cfu in 107 enterobacteria. Both methods, detection of PCR products by agarose gel electrophoresis and measurement of fluorescence signals by the TaqMan method yielded comparable results, i.e. that at ΔRQ values above ΔRQthreshold PCR product bands were visible in agarose gels, whereas at ΔRQ values around ΔRQthreshold also in agarose gels PCR products were below the detection limit. After optimizing detection tests for all virulence factors/toxins, TaqMan™-PCR was set up for routine testing of biological specimen for the presence of pathogenic E. coli bacteria. Results of TaqMan™-PCR were compared to agarose gel electrophoresis.
- The following example will illustrate the invention further. It is, however, not to be construed as limiting.
- In order to verify TaqMan™-PCR performance and to test for the occurence of pathogenicE. coli screening of 100 stool specimens from children of age 0 to 10 years with the clinical symptoms of diarrhea was undertaken. The materials and methods used in the test are described in more detail below under item 2.
- Collection of specimen took place fom June to October 1996. All samples in this study were derived from the area of Southern Bavaria. Stool specimen were plated on McConkey agar, incubated overnight and enterobacteria were collected. DNA was isolated and used as template in PCR reactions containing specific primers and fluorigenic probes for sltI, sltII, LT, ST, EAF-plasmid, eae-gene, inv-plasmid, and pCVD432. For verification of the integrity of DNA from individual preparations a control PCR reaction was set up, containing primers and an internal fluorigenic probe for amplification of the parC gene ofE. coli. As a positive assay control, one PCR reaction was performed within each assay, where DNA from a positive control strain for the respective virulence factor/toxin was present.. Applying this method reliable, specific and sensitive detection of all target genes could be achieved. Systematic analysis of 100 stool specimen derived from children suffering from diarrhea yielded 22 samples where one, two or three of the virulence factors/toxins of pathogenic E. coli could be detected. In detail, 2 patients harbored EHEC (one with hemorrhagic colitis and one developed HUS). 3 patients tested positive for ETEC, 16 for EPEC, 1 for EIEC, and 8 for EaggEC (see Table 4). The patient suffering from hemorrhagic colitis tested positive for sltI and eae, the patient developing HUS tested positive for sltI, sltII and eae. One patient simultaneously harbored ETEC (LT+,ST+), EPEC (eae+), and EaggEC (pCVD342+), one patient tested positive for EIEC (inv+) and EaggEC (pCVD342+), two stool specimen contained EPEC (eae+) and EaggEC (pCVD342).
- Enterobacteria from the two patients with EHEC were hybridized with sltI and sltII gene probes for testing accuracy and specificity of TaqMan™-PCR. In the case of patient one, where TaqMan™-PCR was positive for sltI, only colonies hybridizing with sltI could be found. Colonies of patient two, where TaqMan™-PCR was positive for sltI and sltII, hybridized with probes for sltI and sltII. Positive colonies were picked and biochemically typed asE. coli.
- Antibiotic susceptibilty testing revealed that EHEC strains were sensitive to broad spectrum penicillins, cephalosporins and gyrase inhibitors.
- a) Bacterial strains, media, culture and DNA preparation: A number of EHEC, ETEC, EPEC, EIEC, and EaggECE. coli strains were used as controls for accurate PCR amplification and were kindly provided by H. Karch, Würzburg, Germany and H. Beutin, Berlin, Germany (see Table 1) As a strain not harboring these virulence genes E. coli ATCC 11775 was used. For TaqMan™-PCR optimization, positive control strains were grown on McConkey agar (Becton Dickinson, Germany) at 37° C. After overnight culture, bacteria were collected and resuspended in 0.9% NaCl solution. Turbidity was adjusted to McFarland 0.5. DNA was either prepared by boiling (95° C., 10 min) or isolated using QiaAmp tissue kit spin prep columns (Qiagen, Germany). 10 μl of DNA suspension was used for PCR. Detection of pathogenic E. coli strains from stool specimen of humans or cows was performed after spreading an appropriate amount of stool on McConkey plates. After overnight culture all bacterial colonies from the surface of the McConkey plates were collected and processed as detailed above.
- b) PCR-cyling: PCR recations were set up in 70 μl final volume in thin-walled 0.2 ml “optical PCR-tubes” (Perkin Elmer, Germany). The reaction mix contained: 10 μl of bacterial lysate, 5.25 μl 25 mmol MgCl2, 7 μl 10×PCR buffer, 40 pmol primers, 20 pmol specific fluorogenic probe, 150 μM of each dATP, dTTP, dGTP, dCTP (Perkin Elmer), 1 U AmpliTaq-Polymerase (Perkin Elmer). A Perkin Elmer model 9600 thermal cycler was used for PCR cycling. Initial denaturation of bacterial DNA was performed by heating for 5 min to 94° C. All cycles included a denaturation step for 15 sec at 94° C., annealing for 1 min 30 sec at 55° C., and extension for 1 min 30 sec at 65° C. 35 cycles were performed.
- c) Post-PCR processing: After completion of cycling, the fluorescence intensities of the reporter dye, FAM, and the quencher dye, TAMRA, were determined using a Perkin Elmer LS50B luminiscence spectrophotometer equipped with a plate reader and modified for fluorescence measurements of PCR reactions in optical tubes. ΔRQ values were calculated as described in (74). A ΔRQthreshold value was calculated on the basis of a 99% confidence interval above the mean of the triplicate no template controls (ΔRQthreshold=6.95×stdmean of no template controls). PCR reactions were scored positive if ΔRQsample>ΔRQthreshold was given. For verification of the sensitivity of TaqMan™-measurements, PCR products were subjected to agarose gel electrophoresis. 15 μl of sample were loaded with 2 μl sample buffer. PCR products were separated in 2% agarose gels containing ethidium bromide at 100V for 35 min. DNA was visualized under UV light and a digital image file was obtained using the Eagle EyeII System (Stratagene).
- d) Verification of PCR amplificates: PCR product obtained from templates of respective positive control strains were directly subcloned into the TA cloning vector (Invitrogen, Germany) for verification of specificity of PCR amplification. After transfection (CaCl2-method) of DH5α bacteria with the ligation products, plasmid containing bacteria were selected on ampicillin (Sigma, Germany) containing LB plates. Plasmid DNA was purified with Qiagen DNA purification columns (Quiagen, Germany). Inserts were PCR-cycle sequenced employing dideoxy-nucleotides conjugated to 4 dyes (DNA Dye terminator cycle sequencing kit, Perkin Elmer, Germany). Sequences were obtained with an Applied Biosystems model 373A (Applied Biosystems, Germany). Insert sequences were aligned to published sequences as referenced in Table 1 using the McDNAsis programme (Appligene, Great Britain). Sequence comparisons verified that the PCR products were identical to the respective virulence factors or toxins.
- e) Sensitivity of TaqMan™ technique: For determination of the sensitivity of the TaqMan method, serial log-step dilutions of positive control strains were performed in a solution containing 107 cfu of E. coli reference strain ATCC 11775 DNA was either prepared by the boiling method (see above) or purified using spin prep columns designed for isolation of genomic bacterial DNA (Qiagen, Germany). Purification was according to the protocol of the manufacturer. The detection limit for sltl containing strains was determined with 103 cfu among 107 E. coli and for sltII containing strains as 103.5 among 107.
- f) Colony hybridisation and isolation of EHEC bacteria: EHEC bacterial strains and stool samples from patients testing positive in sltI or sltII TaqMan™-PCR were subjected to colony hybridisation. Briefly, bacteria were plated on McConkey agar plates such that single colonies could be seen. Bacteria were blotted on nylon membranes (Genescreen Plus, NEN, Germany), cracked (1% SDS), denatured (0.5M NaOH, 1.5M NaCl), neutralized (1M TRIS, 1.5M NaCl), and washed (20×SSC). Membranes were baked at 80° C. for 2 hours. DNA probes specific for sltI or sltII were labelled with fluorescein (Gene-Images random prime labelling module, Amersham, Germany). Afterwards, filters were hybridized with labelled probes. Hybridization was verified by non-radioactive detection system employing anti-FITC peroxidase mAb and ECL detection module (Gene-Images CDP-Star detection module, Amersham, Germany). Bacterial colonies hybridizing with the probe and non-hybridizing colonies were picked, verified by TaqMan-PCR and tested for antibiotic susceptibility. Antibiotic susceptibility testing. EHEC and non-EHECE. coli were picked from McConkey plates after testing for sItI or sltII or both toxin genes in colony hybridazation and MIC testing was performed according to NCCLS guidelines for enterobacteria.
TABLE 1 E. coli strains - virulence factors/toxins Strain Group number Serotype Virulence factor/toxin EHEC 1193/89 O157:H- sltI, eae 3574/92 O157:H7 sltII, eae A9167C O157:H7 sltI, sltIIc, eae 5769/87 O157:H7 sltI, sltII, eae 427/89 O157:H- sltI, sltIIc, eae 1249/87 O157:H7 sltII, sltIIc, eae ETEC 147/1 O128:H- ST 164/82 O148:H28 LT EPEC 111/87 O111 EAF, eae 12810 O114:H2 EAF, eae EIEC 76-5 O143 inv-plasmid 12860 O124 inv-plasmid EaggEC pCVD432 plasmid control ATCC 11775 — -
TABLE 2 Primers for detection of pathogenic E. coli. W is A/T, R is A/G, D is A/G/T, Y is C/T and K is G/T. Size Virulence location of factor/ Sequence of PCR Gen- Group toxin Primer (5′→3′) primer product bankRef. Ref. ETEC LT LT-1 gcg tta cta tcc tct 874-895 339 S60731 (84) cta tgt g LT-2 agt ttt cca tac tga 1213-1192 ttg ccg c ST ST-1 tcc ctc agg atg cta 100-120 260 M34916 (36) aac cag ST-2a tcg att tat tca aca 360-339 aag caa c EaggEC pCVD432 EA-1 ctg gcg aaa gac 66-87 629 X81423 (40, 50) plasmid tgt atc att g EA-2 taa tgt ata gaa atc 695-674 cgc tgt t EIEC inv- EI-1 ttt ctg gat ggt atg 17786-17806 303 D50601 (38, 48) plasmid gtg agg emb EI-2 ctt gaa cat aag 18089-18069 gaa ata aac EPEC EAF EP-1 cag ggt aaa aga 546-568 398 X76137 (37, 85) plasmid aag atg ata ag EP-2 aat atg ggg acc 944-923 atg tat tat c eae EPeh-1 ccc gga ccc ggc 91-113 872 Z11541 (86) aca agc ata ag EPeh-2 agt ctc gcc agt att 963-942 cgc cac c EHEC sltI sltI-1 atg aaa aaa aca 1113-1135 287 Z36899 (77, 78) tta tta ata gc sltI-2 tca cyg agc tat tct 1400-1376 gag tca acg sltII sltII-1 atg aag aag atr 1148-1178 265 L11079 (79-83) wtt rtd gcr sltII-2 gyt tta tty g 1413-1385 tca gtc atw att aaa ctk cac yts rgc aaa kcc control parC par-1 aac ctg ttc agc gcc 141-161 260 M58408 (87) gca ttg par-2 aca acc ggg att 401-381 cgg tgt aac -
TABLE 3 TaqMan ™-probes used for detection of pathogenic E. coli virulence Gen- factor/ Probe for Taqman ™ bank Group toxin (FAM-5′→3′-TAMRA) bp Ref. Ref. ETEC LT agc tcc cca gtc tat tac aga act atg 903-929 S60731 (84) ST aca tac gtt aca gac ata atc aga atc ag 334-306 M34916 (36) EaggEC pCVD432 ctc ttt taa ctt atg ata tgt aat gtc tgg 668-639 X81423 (40, 50) plasmid EIEC inv- caa aaa cag aag aac cta tgt cta cct 18063-18037 D50601 (38, 48) plasmid emb EPEC EAF- ctt gga gtg atc gaa cgg gat cca aat 575-601 X76137 (37, 85) plasmid eae taa acg ggt att atc acc aga aaa atc c 935-908 Z11541 (86) EHEC sltI tcg ctg aat ccc cct cca tta tga cag gca 1367-1338 Z36899 (77, 78) sltII cag gta ctg gat ttg att gtg aca gtc att 1371-1342 L11079 (79-83) control parC atg tct gaa ctg ggc ctg aat gcc agc 169-199 M58408 (87) gcc -
TABLE 4 Frequency of pathogenic E. coli in stool samples of children with diarrhea (n = 100) Agar gel TaqMan: electrophores virulence number of is: number of factor/ positive positive pathogenic Group toxin isolates isolates group ETEC LT 2 2 5 ST 3 3 EaggEC 60 kb 8 8 8 plasmid EIEC inv plasmid 1 1 1 EPEC EAF plasmid 1 1 16 eae 15 15 EHEC sltI 2 2 2 sltII 1 1 control parC 100 100 - 1. Centers for Disease Control. 1982. Isolation ofE. coli O157:H7 from sporadic cases of hemorrhagic colitis-United States. MMWR. Morb. Mortal. Wkly. Rep. 31:580, 585.
- 2. Karmali, M. A., M. Petric, C. Lim, P. C. Fleming, and B. T. Steele. 1983.Escherichia coli cytotoxin, haemolytic-uraemic syndrome, and haemorrhagic colitis [letter]. Lancet 2:1299.
- 3. Karmali, M. A., M. Petric, C. Lim, and P. C. Fleming. 1985. The association between idiopatic hemolitic uremic syndrom and infection by verotoxin-producingEscherichia coli. J. Infect. Dis. 151:775.
- 4. Riley, L. W., R. S. Remis, S. D. Helgerson, H. B. McGee, J. G. Wells, B. R. Davis, R. J. Hebert, E. S. Olcott, L. M. Johnson, N. T. Hargrett, P. A. Blake, and M. L. Cohen. 1983. Hemorrhagic colitis associated with a rareEscherichia coli serotype. N. Engl. J. Med. 308:681.
- 5. Pai, C. H., R. Gordon, H. V. Sims, and L. E. Bryan. 1984. Sporadic cases of hemorrhagic colitis associated withEscherichia coli O157:H7. Clinical, epidemiologic, and bacteriologic features. Ann. Intern. Med. 101:738.
- 6. Borczyk, A. A., M. A. Karmali, H. Lior, and L. M. Duncan. 1987. Bovine reservoir for verotoxin-producingEscherichia coli O157: H7 [letter]. Lancet 1:98.
- 7. Blanco, J. E., M. Blanco, and J. Blanco. 1995. [Enterotoxigenic, verotoxigenic, and necrotoxigenicEscherichia coli in food and clinical samples. Role of animals as reservoirs of strains pathogenic for humans]. Microbiologia. 11:97.
- 8. Ostroff, S. M., P. M. Griffin, R. V. Tauxe, L. D. Shipman, K. D. Greene, J. G. Wells, J. H. Lewis, P. A. Blake, and J. M. Kobayashi. 1990. A statewide outbreak ofEscherichia coli O157:H7 infections in Washington State. Am. J. Epidemiol. 132:239.
- 9. Centers for Disease Control. 1993. Update: multistate outbreak ofEscherichia coli O157:H7 infections from hamburgers-western United States, 1992-1993. MMWR 42:258.
- 10. Nathan, R. 1996. JapansE. coli outbreak elicits fear, anger. Nature Medicine 2:956.
- 11. Griffin, P. M., S. M. Ostroff, R. V. Tauxe, K. D. Greene, J. G. Wells, J. H. Lewis, and P. A. Blake. 1988. Illnesses associated withEscherichia coli O157:H7 infections. A broad clinical spectrum. Ann. Intern. Med. 109:705.
- 12. Karmali, M. A. 1989. Infection by verocytotoxin-producingEscherichia coli. Clin. Microbiol. Rev. 2:15.
- 13. Kovacs, M. J., J. Roddy, S. Gregoire, W. Cameron, L. Eidus, and J. Drouin. 1990. Thrombotic thrombocytopenic purpura following hemorrhagic colitis due toEscherichia coli O157:H7. Am. J. Med. 88:177.
- 14. O'Brien, A. D. and R. K. Holmes. 1987. Shiga and Shiga-like toxins.Microbiol. Rev. 51:206.
- 15. Karch, H. and J. Bockemühl. 1989. [Infections by enterohemorrhagicEscherichia coli (EHEC): a clinical and microbiologic problem and a challenge for the public health service]. Immun. Infekt. 17:206.
- 16. Siegler, R. L. 1995. The hemolytic uremic syndrome.Pediatr. Clin. North Am. 42:1505.
- 17. Rowe, P. C., W. Walop, H. Lior, and A. M. Mackenzie. 1991. Haemolytic anaemia after childhoodEscherichia coli O 157 .H7 infection: are females at increased risk? Epidemiol. Infect. 106:523.
- 18. 1996. Haufung von EHEC-Erkrankungen in Bayern.Münchner Ärztliche Anzeigen 23:14.
- 19. Doyle, M. P. 1991.Escherichia coli O157:H7 and its significance in foods. Int. J. Food Microbiol. 12:289.
- 20. Belongia, E. A., K. L. MacDonald, G. L. Parham, K. E. White, J. A. Korlath, M. N. Lobato, S. M. Strand, K. A. Casale, and M. T. Osterholm. 1991. An outbreak ofEscherichia coli O157:H7 colitis associated with consumption of precooked meat patties. J. Infect. Dis. 164:338.
- 21. O'Brien, A. D., A. R. Melton, C. K. Schmitt, M. L. McKee, M. L. Batts, and D. E. Griffin. 1993. Profile ofEscherichia coli O157:H7 pathogen responsible for hamburger-borne outbreak of hemorrhagic colitis and hemolytic uremic syndrome in Washington. J. Clin. Microbiol. 31:2799.
- 22. Beutin, L., D. Geier, H. Steinruck, S. Zimmermann, and F. Scheutz. 1993. Prevalence and some properties of verotoxin (Shiga-like toxin)-producingEscherichia coli in seven different species of healthy domestic animals. J. Clin. Microbiol. 31:2483.
- 23. Martin, M. L., L. D. Shipman, J. G. Wells, M. E. Potter, K. Hedberg, I. K. Wachsmuth, R. V. Tauxe, J. P. Davis, J. Arnoldi, and J. Tilleli. 1986. Isolation ofEscherichia coli O157:H7 from dairy cattle associated with two cases of haemolytic uraemic syndrome [letter]. Lancet 2:1043.
- 24. Besser, R. E., S. M. Lett, J. T. Weber, M. P. Doyle, T. J. Barrett, J. G. Wells, and P. M. Griffin. 1993. An outbreak of diarrhea and hemolytic uremic syndrome fromEscherichia coli O157:H7 in fresh-pressed apple cider [see comments]. JAMA 269:2217.
- 25. Read, S. C., C. L. Gyles, R. C. Clarke, H. Lior, and S. McEwen. 1990. Prevalence of verocytotoxigenicEscherichia coli in ground beef, pork, and chicken in southwestern Ontario. Epidemiol. Infect. 105:11.
- 26. Gannon, V. P., R. K. King, J. Y. Kim, and E. J. Thomas. 1992. Rapid and sensitive method for detection of Shiga-like toxin-producingEscherichia coli in ground beef using the polymerase chain reaction. Appl. Environ. Microbiol. 58:3809.
- 27. Bopp, C. A., K. D. Greene, F. P. Downes, E. G. Sowers, J. G. Wells, and I. K. Wachsmuth. 1987. Unusual verotoxin-producingEscherichia coli associated with hemorrhagic colitis. J. Clin. Microbiol. 25:1486.
- 28. Farmer, J. J. and B. R. Davis. 1985. H7 antiserum-sorbitol fermentation medium: a single tube screening medium for detectingEscherichia coli O157:H7 associated with hemorrhagic colitis. J. Clin. Microbiol. 22:620.
- 29. Scotland, S. M., B. Rowe, H. R. Smith, G. A. Willshaw, and R. J. Gross. 1988. Vero cytotoxin-producing strains ofEscherichia coli from children with haemolytic uraemic syndrome and their detection by specific DNA probes. J. Med. Microbiol. 25:237.
- 30. Scotland, S. M., G. A. Willshaw, H. R. Smith, B. Said, N. Stokes, and B. Rowe. 1993. Virulence properties ofEscherichia coli strains belonging to serogroups O26, O55, O111 and O128 isolated in the United Kingdom in 1991 from patients with diarrhoea. Epidemiol. Infect 111:429.
- 31. Russmann, H., E. Kothe, H. Schmidt, S. Franke, D. Harmsen, A. Caprioli, and H. Karch. 1995. Genotyping of Shiga-like toxin genes in non-O157Escherichia coli strains associated with haemolytic uraemic syndrome. J. Med. Microbiol. 42:404.
- 32. Koneman, E. W., S. D. Allen, W. M. Janda, P. C. Schreckenberger, and C. W. j. Washington. 1992. The Enterobacteriaceae. In Diagnostic Microbiology. J.B. Lippincott Company, Philadelphia. 132-133.
- 33. Edelman, R. and N. F. Pierce. 1984. From the National Institute of Allergy and Infectious Diseases. Summary of the 19th United States-Japan Joint Cholera Conference.J. Infect. Dis. 149:1014.
- 34. Hart, C. A., R. M. Batt, and J. R. Saunders. 1993. Diarrhoea caused byEscherichia coli. Ann. Trop. Trop. Paediatr. 13:121.
- 35. Chapman, P. A. and C. M. Daly. 1993. Evaluation of non-radioactive trivalent DNA probe (LT, ST1a, ST1b) for detecting enterotoxigenicEscherichia coli. J. Clin. Pathol. 46:309.
- 36. Moseley, S. L., J. W. Hardy, M. I. Hug, P. Echeverria, and S. Falkow. 1983. Isolation and nucleotide sequence determination of a gene encoding a heat-stable enterotoxin ofEscherichia coli. Infect. Immun. 39:1167.
- 37. Jerse, A. E., J. Yu, B. D. Tall, and J. B. Kaper. 1990. A genetic locus of enteropathogenicEscherichia coli necessary for the production of attaching and effacing lesions on tissue culture cells. Proc. Natl. Acad. Sci. U.S.A. 87:7839.
- 38. Taylor, D. N., P. Echeverria, O. Sethabutr, C. Pitarangsi, U. Leksomboon, N. R. Blacklow, B. Rowe, R. Gross, and J. Cross. 1988. Clinical and microbiologic features of Shigella and enteroinvasiveEscherichia coli infections detected by DNA hybridization. J. Clin. Microbiol. 26:1362.
- 39. Prats, G. and T. Llovet. 1995. [EnteroinvasiveEscherichia coli. Pathogenesis and epidemiology]. Microbiologia. 11:91.
- 40. Nataro, J. P., Y. Deng, D. R. Maneval, A. L. German, W. C. Martin, and M. M. Levine. 1992. Aggregative adherence fimbriae I of enteroaggregativeEscherichia coli mediate adherence to HEp-2 cells and hemagglutination of human erythrocytes. Infect. Immun. 60:2297.
- 41. Cohen, M. B., J. A. Hawkins, L. S. Weckbach, J. L. Staneck, M. M. Levine, and J. E. Heck. 1993. Colonization by enteroaggregativeEscherichia coli in travelers with and without diarrhea. J. Clin. Microbiol. 31:351.
- 42. Chang, P. P., J. Moss, E. M. Twiddy, and R. K. Holmes. 1987. Type II heat-labile enterotoxin ofEscherichia coli activates adenylate cyclase in human fibroblasts by ADP ribosylation. Infect. Immun. 55:1854.
- 43. Pickett, C. L., D. L. Weinstein, and R. K. Holmes. 1987. Genetics of type IIa heat-labile enterotoxin ofEscherichia coli: operon fusions, nucleotide sequence, and hybridization studies. J. Bacteriol. 169:5180.
- 44. Giron, J. A., M. S. Donnenberg, W. C. Martin, K. G. Jarvis, and J. B. Kaper. 1993. Distribution of the bundle-forming pilus structural gene (bfpA) among enteropathogenicEscherichia coli. J. Infect. Dis. 168:1037.
- 45. Karch, H., J. Heesemann, R. Laufs, A. D. O'Brien, C. O. Tacket, and M. M. Levine. 1987. A plasmid of enterohemorrhagicEscherichia coli O157:H7 is required for expression of a new fimbrial antigen and for adhesion to epithelial cells. Infect. Immun. 55:455.
- 46. Nataro, J. P., M. M. Baldini, and J. B. Kaper. 1985. Detection of an Adherence Factor of EnteropathogenicEschierichia coli with a DNA probe. J. Infect. Dis. 152:560.
- 47. Watanabe, H., E. Arakawa, K. Ito, J. Kato, and A. Nakamura. 1990. Genetic analysis of an invasion region by use of a Tn3-lac transposon and identification of a second positive regulator gene, invE, for cell invasion of Shigella sonnei: significant homology of invE with ParB of plasmid P1.J. Bacteriol. 172:619.
- 48. Sasakawa, C., K. Komatsu, T. Tobe, T. Suzuki, and M. Yoshikawa. 1993. Eight genes in region 5 that form an operon are essential for invasion of epithelial cells by Shigella flexneri 2a.J. Bacteriol. 175:2334.
- 49. Echeverria, P., O. Serichantalerg, S. Changchawalit, B. Baudry, M. M. Levine, F. Orskov, and I. Orskov. 1992. Tissue culture-adherentEscherichia coli in infantile diarrhea. J. Infect. Dis. 165:141.
- 50. Schmidt, H., C. Knop, S. Franke, S. Aleksic, J. Heesemann, and H. Karch. 1995. Development of PCR for screening of enteroaggregativeEscherichia coli. J. Clin. Microbiol. 33:701.
- 51. Faruque, S. M., K. Haider, M. M. Rahman, A. R. Abdul Alim, A. H. Baqui, Q. S. Ahmad, K. M. Hossain, and M. J. Albert. 1992. Evaluation of a DNA probe to identify enteroaggregativeEscherichia coli from children with diarrhoea in Bangladesh. J. Diarrhoeal. Dis. Res. 10:31.
- 52. Yamamoto, T., P. Echeverria, and T. Yokota. 1992. Drug resistance and adherence to human intestines of enteroaggregativeEscherichia coli. J. Infect. Dis. 165:744.
- 53. Savarino, S. J., A. Fasano, J. Watson, B. M. Martin, M. M. Levine, S. Guandalini, and P. Guerry. 1993. EnteroaggregativeEscherichia coli heat-stable enterotoxin 1 represents another subfamily of E. coli heat-stable toxin. Proc. Natl. Acad. Sci. U.S.A. 90:3093.
- 54. Bennett, A. R., S. MacPhee, and R. P. Betts. 1995. Evaluation of methods for the isolation and detection ofEscherichia coli O157 in minced beef. Lett. Appl. Microbiol. 20:375.
- 55. March, S. B. and S. Ratnam. 1986. Sorbitol-MacConkey medium for detection ofEscherichia coli O157:H7 associated with hemorrhagic colitis. J. Clin. Microbiol. 23:869.
- 56. Kleanthous, H., N. K. Fry, H. R. Smith, R. J. Gross, and B. Rowe. 1988. The use of sorbitol-MacConkey agar in conjunction with a specific antiserum for the detection of Vero cytotoxin-producing strains ofEscherichia coli O157. Epidemiol. Infect. 101:327.
- 57. March, S. B. and S. Ratnam. 1989. Latex agglutination test for detection ofEscherichia coli serotype O157. J. Clin. Microbiol. 27:1675.
- 58. Beutin, L., S. Aleksic, S. Zimmermann, and K. Gleier. 1994. Virulence factors and phenotypical traits of verotoxigenic strains ofEscherichia coli isolated from human patients in Germany. Med. Microbiol. Immunol. Berl. 183:13.
- 59. Stroeher, U. H., L. Bode, L. Beutin, and P. A. Manning. 1993. Characterization and sequence of a 33-kDa enterohemolysin (Ehly 1)-associated protein inEscherichia coli. Gene 132:89.
- 60. Johnson, R. P., R. J. Durham, S. T. Johnson, L. A. MacDonald, S. R. Jeffrey, and B. T. Butman, 1995. Detection ofEscherichia coli O157:H7 in meat by an enzyme-linked immunosorbent assay, EHEC-Tek. Appl. Environ. Microbiol. 61:386.
- 61. Padhye, N. V. and M. P. Doyle. 1991. Rapid procedure for detecting enterohemorrhagicEscherichia coli O157:H7 in food. Appl. Environ. Microbiol. 57:2693.
- 62. Clark, C. G., S. Johnson, and R. P. Johnson. 1995. Further characterisation of a monoclonal antibody reactive withEscherichia coli O157:H7. J. Med. Microbiol. 43:262.
- 63. Karmali, M. A., M. Petric, M. Winkler, M. Bielaszewska, J. Brunton, N. van de Kar, T. Morooka, G. B. Nair, S. E. Richardson, and G. S. Arbus. 1994. Enzyme-linked immunosorbent assay for detection of immunoglobulin G antibodies toEscherichia coli Vero cytotoxin 1. J. Clin. Microbiol. 32:1457.
- 64. Gunzer, F., H. Bohm, H. Russmann, M. Bitzan, S. Aleksic, and H. Karch. 1992. Molecular detection of sorbitol-fermentingEscherichia coli O157 in patients with hemolytic-uremic syndrome. J. Clin. Microbiol. 30:1807.
- 65. Bockemuhl, J., S. Aleksic, and H. Karch. 1992. Serological and biochemical properties of Shiga-like toxin (verocytotoxin)-producing strains ofEscherichia coli, other than O-group 157, from patients in Germany. Int. J. Med. Microbiol. Virol. Parasitol. Infect. Dis. 276:189.
- 66. Smith, H. R., S. M. Scotland, G. A. Willshaw, C. Wray, I. M. McLaren, T. Cheasty, and B. Rowe. 1988. Vero cytotoxin production and presence of VT genes inEscherichia coli strains of animal origin. J. Gen. Microbiol. 134:829.
- 67. Karch, H. and T. Meyer. 1989. Evaluation of oligonucleotide probes for identification of shiga-like-toxin-producingEscherichia coli. J. Clin. Microbiol. 27:1180.
- 68. Jackson, M. P. 1991. Detection of Shiga Toxin-Producing Shighella dysenteriae Type 1 andEscherichia Coli by Using Polymerase Chain Reaction with Incorporation of Digixigenin-11-dUTP. J. Clin. . Microbiol. 29:1910.
- 69. Johnson, W. M., D. R. Pollard, H. Lior, S. D. Tyler, and K. R. Rozee. 1990. Differentiation of genes coding forEscherichia coli verotoxin 2 and the verotoxin associated with porcine edema disease (VTe) by the polymerase chain reaction. J. Clin. Microbiol. 28:2351.
- 70. Johnson, W. M., S. D. Tyler, G. Wang, and H. Lior. 1991. Amplification by the polymerase chain reaction of a specific target sequence in the gene coding forEscherichia coli verotoxin (VTe variant). FEMS Microbiol. Lett. 68:227.
- 71. Karch, H. and T. Meyer. 1989. Single primer pair for amplifying segments of distinct shiga-like-toxin genes by polymerase chain reaction.J. Clin. Microbiol. 27:2751.
- 72. Pollard, D. and W. M. Johnson. 1990. Rapid and Specific Detection of Verotoxin Genes inEscherichia Coli by the Polimerase Chain Reaction. J. Clin. Microbiol. 28:540.
- 73. Holland, P. M., R. D. Abramson, R. Watson, and D. H. Gelfand. 1991. Detection of specific polymerase chain reaction product by utilizing the 5′- - - 3′ exonuclease activity of Thermus aquaticus DNA polymerase.Proc. Natl. Acad. Sci. U.S.A. 88:7276.
- 74. Bassler, H. A., S. J. Flood, K. J. Livak, J. Marmaro, R. Knorr, and C. A. Batt. 1995. Use of a fluorogenic probe in a PCR-based assay for the detection of Listeria monocytogenes.Appl. Environ. Microbiol. 61:3724.
- 75. Livak, K. J., S. J. Flood, J. Marmaro, W. Giusti, and K. Deetz. 1995. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization.PCR. Methods Appl. 4:357.
- 76. Förster, V. 1948. Zwischenmolekulare Energiewanderung und Fluoreszenz.Annals of Physics (Leipzig) 2:55.
- 77. Paton, A. W., J. C. Paton, P. N. Goldwater, and P. A. Manning. 1993. Direct detection ofEscherichia coli Shiga-like toxin genes in primary fecal cultures by polymerase chain reaction. J. Clin. Microbiol. 31:3063.
- 78. Paton, A. W., J. C. Paton, P. N. Goldwater, M. W. Heuzenroeder, and P. A. Manning. 1993. Sequence of a variant Shiga-like toxin type-I operon ofEscherichia coli O111:H-.Gene 129:87.
- 79. Paton, A. W., J. C. Paton, and P. A. Manning. 1993. Polymerase chain reaction amplification, cloning and sequencing of variantEscherichia coli Shiga-like toxin type II operons. Microb. Pathog. 15:77.
- 80. Gyles, C. L., S. A. De Grandis, C. MacKenzie, and J. L. Brunton. 1988. Cloning and nucleotide sequence analysis of the genes determining verocytotoxin production in a porcine edema disease isolate ofEscherichia coli. Microb. Pathog. 5:419.
- 81. Gannon, V. P., C. Teerling, S. A. Masri, and C. L. Gyles. 1990. Molecular cloning and nucleotide sequence of another variant of theEscherichia coli Shiga-like toxin II family. J. Gen. Microbiol. 136:1125.
- 82. Schmitt, C. K., M. L. McKee, and A. D. O'Brien. 1991. Two copies of Shiga-like toxin II-related genes common in enterohemorrhagicEscherichia coli strains are responsible for the antigenic heterogeneity of the O157:H-strain E32511. Infect. Immun. 59:1065.
- 83. Schmidt, H., M. Montag, J. Bockemuhl, J. Heesemann, and H. Karch. 1993. Shiga-like toxin II-related cytotoxins inCitrobacter freundii strains from humans and beef samples. Infect. Immun. 61:534.
- 84. Inoue, T., T. Tsuji, M. Koto, S. Imamura, and A. Miyama. 1993. Amino acid sequence of heat-labile enterotoxin from chicken enterotoxigenicEscherichia coli is identical to that of human strain H 10407. FEMS Microbiol. Lett. 108:157.
- 85. Franke, J., H. Schmidt, and H. Karch. 1994. Nucleotide Sequence Analysis of EnteropathogenicEscherichia coli (EPEC) Adherence Factor Probe and Development of PCR for Rapid Detection of EPEC Harboring Virulence Plasmids. J. Clin. Microbiol. 32:2460.
- 86. Yu, J. and J. B. Kaper. 1992. Cloning and characterization of the eae gene of enterohaemorrhagicEscherichia coli O157:H7. Mol. Microbiol. 6:411.
- 87. Kato, J., Y. Nishimura, R. Imamura, H. Niki, S. Hiraga, and H. Suzuki. 1990. New topoisomerase essential for chromosome segregation inE. coli [published erratum appears in Cell 1991 Jun. 28; 65(7):1289].Cell 63:393.
- 88. Zhao, S., S. E. Mitchell, J. Meng, M. P. Doyle, and S. Kresovich. 1995. Cloning and nucleotide sequence of a gene upstream of the eaeA gene of enterohemorrhagicEscherichia coli O157:H7. FEMS Microbiol. Lett. 133:35.
- 89. Paton, A. W. and J. C. Paton. 1996. Enterobacter cloacae producing a shiga-like toxin II-related cytotoxinn associated with a case of hemolytic-uremic syndrome.J. Clin. Microbiol. 34:463.
-
- 91. Karch, H., C. Janetzki-Mittmann, S. Aleksic, and M. Datz. 1996. Isolation of EnterohemorrhagicEscherichia coli O157 strains from patients with hemolytic-uremic symdrome by using immunomagnetic separation, DNA-based methods, and direct culture. J. Clin. Microbiol. 34:516.
- 92. Huppertz, H. I., D. Busch, H. Schmidt, S. Aleksic, and H. Karch. 1996. Diarrhea in young children associated withEscherichia coli non-O157 organisms that produce shiga-like toxin. J. Pediatrics 128:341.
-
1 30 1 22 DNA Escherichia coli CDS (1)...(22) 1 gcg tta cta tcc tct cta tgt g 22 Ala Leu Leu Ser Ser Leu Cys 1 5 2 22 DNA Escherichia coli CDS (1)...(22) 2 agt ttt cca tac tga ttg ccg c 22 Ser Phe Pro Tyr * Leu Pro 1 5 3 21 DNA Escherichia coli CDS (1)...(21) 3 tcc ctc agg atg cta aac cag 21 Ser Leu Arg Met Leu Asn Gln 1 5 4 22 DNA Escherichia coli CDS (1)...(22) 4 tcg att tat tca aca aag caa c 22 Ser Ile Tyr Ser Thr Lys Gln 1 5 5 21 DNA Escherichia coli CDS (1)...(21) 5 aac tgc tgg gta tgt ggc tgg 21 Asn Cys Trp Val Cys Gly Trp 1 5 6 21 DNA Escherichia coli CDS (1)...(21) 6 tgc tga cct gcc tct tcc atg 21 Cys * Pro Ala Ser Ser Met 1 5 7 22 DNA Escherichia coli CDS (1)...(22) 7 ctg gcg aaa gac tgt atc att g 22 Leu Ala Lys Asp Cys Ile Ile 1 5 8 22 DNA Escherichia coli CDS (1)...(22) 8 taa tgt ata gaa atc cgc tgt t 22 * Cys Ile Glu Ile Arg Cys 1 5 9 21 DNA Escherichia coli CDS (1)...(21) 9 ttt ctg gat ggt atg gtg agg 21 Phe Leu Asp Gly Met Val Arg 1 5 10 21 DNA Escherichia coli CDS (1)...(21) 10 ctt gaa cat aag gaa ata aac 21 Leu Glu His Lys Glu Ile Asn 1 5 11 23 DNA Escherichia coli CDS (1)...(23) 11 cag ggt aaa aga aag atg ata ag 23 Gln Gly Lys Arg Lys Met Ile 1 5 12 22 DNA Escherichia coli CDS (1)...(22) 12 aat atg ggg acc atg tat tat c 22 Asn Met Gly Thr Met Tyr Tyr 1 5 13 23 DNA Escherichia coli CDS (1)...(23) 13 ccc gca ccc ggc aca agc ata ag 23 Pro Ala Pro Gly Thr Ser Ile 1 5 14 22 DNA Escherichia coli CDS (1)...(22) 14 agt ctc gcc agt att cgc cac c 22 Ser Leu Ala Ser Ile Arg His 1 5 15 23 DNA Escherichia coli CDS (1)...(23) 15 atg aaa aaa aca tta tta ata gc 23 Met Lys Lys Thr Leu Leu Ile 1 5 16 24 DNA Escherichia coli CDS (1)...(24) 16 tca cyg agc tat tct gag tca agc 24 Ser Xaa Ser Tyr Ser Glu Ser Ser 1 5 17 31 DNA Escherichia coli CDS (1)...(31) 17 atg aag aag atr wtt rtd gcr gyt tta tty g 31 Met Lys Lys Xaa Xaa Xaa Xaa Xaa Leu Phe 1 5 10 18 33 DNA Escherichia coli CDS (1)...(33) 18 tca gtc atw att aaa ctk cac yts rgc aaa kcc 33 Ser Val Xaa Ile Lys Xaa His Xaa Xaa Lys Xaa 1 5 10 19 27 DNA Escherichia coli CDS (1)...(27) 19 agc tcc cca gtc tat tac aga act atg 27 Ser Ser Pro Val Tyr Tyr Arg Thr Met 1 5 20 29 DNA Escherichia coli CDS (1)...(29) 20 aca tac gtt aca gac ata atc aga atc ag 29 Thr Tyr Val Thr Asp Ile Ile Arg Ile 1 5 21 30 DNA Escherichia coli CDS (1)...(30) 21 atg aag ggg cga agt tct ggc tca atg tgc 30 Met Lys Gly Arg Ser Ser Gly Ser Met Cys 1 5 10 22 30 DNA Escherichia coli CDS (1)...(30) 22 ctc ttt taa ctt atg ata tgt aat gtc tgg 30 Leu Phe * Leu Met Ile Cys Asn Val Trp 1 5 23 27 DNA Escherichia coli CDS (1)...(27) 23 caa aaa cag aag aac cta tgt cta cct 27 Gln Lys Gln Lys Asn Leu Cys Leu Pro 1 5 24 27 DNA Escherichia coli CDS (1)...(27) 24 ctt gga gtg atc gaa cgg gat cca aat 27 Leu Gly Val Ile Glu Arg Asp Pro Asn 1 5 25 28 DNA Escherichia coli CDS (1)...(28) 25 taa acg ggt att atc aac aga aaa atc c 28 * Thr Gly Ile Ile Asn Arg Lys Ile 1 5 26 30 DNA Escherichia coli CDS (1)...(30) 26 tcg ctg aat ccc cct cca tta tga cag gca 30 Ser Leu Asn Pro Pro Pro Leu * Gln Ala 1 5 27 30 DNA Escherichia coli CDS (1)...(30) 27 cag gta ctg gat ttg att gtg aca gtc att 30 Gln Val Leu Asp Leu Ile Val Thr Val Ile 1 5 10 28 21 DNA Escherichia coli CDS (1)...(21) 28 aac ctg ttc agc gcc gca ttg 21 Asn Leu Phe Ser Ala Ala Leu 1 5 29 21 DNA Escherichia coli CDS (1)...(21) 29 aca acc ggg att cgg tgt aac 21 Thr Thr Gly Ile Arg Cys Asn 1 5 30 30 DNA Escherichia coli CDS (1)...(30) 30 atg tct gaa ctg ggc ctg aat gcc agc gcc 30 Met Ser Glu Leu Gly Leu Asn Ala Ser Ala 1 5 10
Claims (10)
1. A method for the detection of pathogenic E. coli in a sample comprising PCR amplification of DNA isolated from said sample using a set of oligonucleotide primers specific for virulence factors/toxins of pathogenic E. coli selected from
primers that hybridise to a gene encoding heat labile toxin, or heat stabile toxin for the amplification of a DNA sequence characteristic for enterotoxigenic E. coli;
primers that hybridise to a gene encoding heat stabile toxin for the amplification of a DNA sequence characteristic for enteroaggregative E. coli;
primers that hybridise to the pCVD432 plasmid for the amplification of a DNA sequence characteristic for enteroaggregative E. coli;
primers that hybridise to the inv-plasmid for the amplification of a DNA sequence contained in enteroinvasive E. coli;
primers that hybridise to the EAF plasmid, or the eae gene for the amplification of a DNA sequence characteristic for enteropathogenic E. coli; and/or
primers that hybridise to the genes encoding shiga-like toxin sltI or sltII for the amplification of a DNA sequence characteristic for enterohemorrhagic E. coli, followed by detection and identification of the amplified product using conventional methods.
2. The method according to claim 1 wherein
LT-1: 5′ GCG TTA CTA TCC TCT CTA TGT G 3′
and
LT-2: 5′ AGT TTT CCA TAC TGA TTG CCG C 3′;
ST-1: 5′ TCC CTC AGG ATG CTA AAC CAG 3′
and
ST-2a: 5′ TCG ATT TAT TCA ACA AAG CAA C 3′;
EASTI-1: 5′ AAC TGC TGG GTA TGT GGC TGG 3′
and
EASTI-2: 5′ TGC TGA CCT GCC TCT TCC ATG 3′;
EA-1: 5′ CTG GCG AAA GAC TGT ATC ATT G 3′
and
EA-2: 5′ TAA TGT ATA GAA ATC CGC TGT T 3′;
EI-1: 5′ TTT CTG GAT GGT ATG GTG AGG 3′
and
EI-2: 5′ CTT GAA CAT AAG GAA ATA AAC 3′;
EP-1: 5′ CAG GGT AAA AGA AAG ATG ATA AG 3′
and
EP-2: 5′ AAT ATG GGG ACC ATG TAT TAT C 3′;
EPeh-1: 5′ CCC GGA CCC GGC ACA AGC ATA AG 3′
and
EPeh-2: 5′ AGT CTC GCC AGT ATT CGC CAC C 3′;
SltI-1: 5′ ATG AAA AAA ACA TTA TTA ATA GC 3′
and
SltI-2: 5′ TCA CYG AGC TAT TCT GAG TCA AGC 3′;
and
SltII-1:
5′ ATG AAG AAG ATR WTT RTD GCR GYT TTA TTY G 3′
and
SltII-2:
5′ TCA GTC ATW ATT AAA CTK CAC YTS RGC AAA KCC 3′
the set of primers that hybridise to the gene encoding heat labile toxin characteristic for enterotoxigenic E. coli is
the set of primers that hybridise to the gene encoding heat stabile toxin characteristic for enterotoxigenic E. coli is
the set of primers that hybridise for the gene encoding heat stabile toxin characteristic for enteroaggregative E. coli is
the set of primers which hybridise to the pCVD432 plasmid is
the set of primers which hybridise to the inv-plasmid is
the set of primers which hybridise to the EAF plasmid is
the set of primers which hybridise to the eae gene is
the primers which hybridises to the gene encoding shiga-like toxin SltI is
the primers which hybridises to the gene encoding shiga-like toxin SltII is
wherein W is A/T, R is A/G, D is A/G/T, Y is C/T and K is G/T.
3. The method according to claims 1 to 2 wherein a polymerase having additional 5′-3′ exonuclease activity is used for the amplification of DNA, and an oligonucleotide probe labelled at the most 5′ base with a fluorescent dye and at the most 3′ base with a fluorescent quencher dye which hybridises within the target DNA is included in the amplification process; said labelled oligonucleotide probe being susceptible to 5′-3′ exonuclease degradation by said polymerase to produce fragments that can be detected by fluorogenic detection methods.
4. The method according to claim 3 wherein
the labelled oligonucleotide probe for the detection of heat labile toxin characteristic for enterotoxigenic E. coli is
5′ AGC TCC CCA CTC TAT TAC AGA ACT ATG 3′;
the labelled oligonucleotide probe for the detection of heat stabile toxin characteristic for enterotoxigenic E. coli is
5′ ACA TAC GTT ACA GAC ATA ATC AGA ATC AG 3′;
the labelled oligonucleotide probe for the detection of heat stabile toxin characteristic for enteroaggregative E. coli is
5′ ATG AAG GGG CGA AGT TCT GGC TCA ATG TGC 3′;
the labelled oligonucleotide probe for the detection of pCVD432 plasmid is
5′ CTC TTT TAA CTT ATG ATA TGT AAT GTC TGG 3′;
the labelled oligonucleotide probe for the detection of the inv-plasmid is;
5′ CAA AAA CAG AAG AAC CTA TGT CTA CCT 3′;
the labelled oligonucleotide probe for the detection of the EAF-plasmid is;
5′° CTT GGA GTG ATC GAA CGG GAT CCA AAT 3′;
the labelled oligonucleotide probe for the detection of the eae gene is
5′ TAA ACG GGT ATT ATC AAC AGA AAA ATC C 3′;
the labelled oligonucleotide probe for the detection of shiga-like toxin SltI gene is
5′ TCG CTG AAT CCC CCT CCA TTA TGA CAG GCA 3′; and
the labelled oligonucleotide probe for the detection of shiga-like toxin SltII gene is
5′ CAG GTA CTG CAT TTG ATT GTG ACA GTC ATT 3′.
5. The method according to claims 3 to 4 wherein the fluorescent reporter dye is 6-carboxy-fluoroscein, tetrachloro-6-carboxy-fluoroscein, or hexachloro-6-carboxy-fluoroscein, and the fluorescent quencher dye is 6-carboxytetramethyl-rhodamine.
6. The method according to claims 1 to 5 wherein the PCR amplification process consists of 35 PCR cycles at a MgCl2 concentration of 5.2 mmol, an annealing temperature of 55° C. and an extension temperature of 65° C.
7. A set of primers useful for PCR amplification of DNA specific for virulence factors/toxins of pathogenic E. coli selected from:
a set of primers that hybridise to a gene encoding heat labile toxin, or heat stabile toxin of enterotoxigenic E. coli;
a set of primers that hybridise to a gene encoding heat stabile toxin of enteroaggregative E. coli;
a set of primers that hybridise to the pCVD432 plasmid of enteroaggregative E. coli;
a set of primers that hybridise to the inv-plasmid of enteroinvasive E. coli;
a set of primers that hybridise to the EAF plasmid, or the eae gene of enteropathogenic E. coli; and
a set of primers that hybridise to the gene encoding shiga-like toxin sltl or sltII of enterohemorrhagic E. coli,
8. The set of primers according to claim 7 wherein
LT-1: 5′ GCG TTA CTA TCC TCT CTA TGT G 3
and
LT-2: 5′ AGT TTT CCA TAC TGA TTG CCG C 3′;
ST-1: 5′ TCC CTC AGG ATG CTA AAC CAG 3′
and
ST-2a: 5′ TCG ATT TAT TCA ACA AAG CAA C 3′;
EASTI-1: 5′ AAC TGC TGG GTA TGT GGC TGG 3′
and
EASTI-2: 5′ TGC TGA CCT GCC TCT TCC ATG 3′;
EA-1: 5′ CTG GCG AAA GAC TGT ATC ATT G 3′
and
EA-2: 5′ TAA TGT ATA GAA ATC CGC TGT T 3′;
EI-1: 5′ TTT CTG GAT GGT ATG GTG AGG 3′
and
EI-2: 5′ CTT GAA CAT AAG GAA ATA AAC 3′;
EP-1: 5′ CAG GGT AAA AGA AAG ATG ATA AG 3′
and
EP-2: 5′ AAT ATG GGG ACC ATG TAT TAT 3′;
EPeh-1: 5′ CCC GGA CCC GGC ACA AGC ATA AG 3′
and
EPeh-2: 5′ AGT CTC GCC AGT ATT CGC CAC C 3′;
SltI-1: 5′ ATG AAA AAA ACA TTA TTA ATA GC 3′
and
SltI-2: 5′ TCA CYG AGC TAT TCT GAG TCA AGC 3′;
SltII-1:
5′ ATG AAG AAG ATR WTT RTD GCR GYT TTA TTY G 3′
and
SltII-2:
5′ TCA GTC ATW ATT AAA CTK CAC YTS RGC AAA KCC 3′
the set of primers which hybridise to the gene encoding heat labile toxin of enterotoxigenic E. coli is
the set of primers which hybridise to the gene encoding heat stabile toxin of enterotoxigenic E. coli is
the set of primers which hybridise to the gene encoding heat stabile toxin of enteroaggregative E. coli is
the set of primers which hybridise to the pCVD432 plasmid is
the set of primers which hybridise to the inv-plasmid is
the set of primers which hybridise to the EAF plasmid is
the set of primers which hybridise to the eae gene is
the set of primers which hybridise to the shiga-like toxin sltI gene is
and
the set of primers which hybridise to the shiga-like toxin sltII is
wherein W is A/T, R is A/G, D is A/G/T, Y is C/T and K is G/T.
9. The set of primers according to claim 8 which in addition to the primers for amplification of target DNA comprise a labelled oligonucleotide probe which is labelled with a fluoroscent reporter dye, such as 6-carboxy-fluoroscein, tetrachloro-6-carboxy-fluoroscein, hexachloro-6-carboxy-fluoroscein, at the most 5′ base and a fluoroscent quencher dye, such as 6-carboxytetramethyl-rhodamine, at the most 3′ base, and have a nucleotide sequence selected from
5′ AGC TCC CCA GTC TAT TAC AGA ACT ATG 3′
which hybridises to a gene encoding heat labile toxin of enterotoxigenic E. coli;
5′ ACA TAC GTT ACA GAC ATA ATC AGA ATC AG 3′
which hybridises to a gene encoding heat stabile toxin of enterotoxigenic E. coli;
5′ ATG AAG GGG CGA AGT TCT GGC TCA ATG TGC 3′
which hybridises to a gene encoding heat stabile toxin of enteroaggregative E. coli;
5′ CTC TTT TAA CTT ATG ATA TGT AAT GTC TGG 3′
which hybridises to the pCVD432 plasmid;
5′ CAA AAA CAG AAG AAC CTA TGT CTA CCT 3′
which hybridises to the inv-plasmid;
5′ CTT GGA GTG ATC GAA CGG GAT CCA AAT 3′
which hybridises to the EAF plasmid;
5′ TAA ACG GGT ATT ATC AAC AGA AAA ATCC 3′
which hybridises to the eae gene;
5′ TCG CTG AAT CCC CCT CCA TTA TGA CAG GCA 3′
which hybridises to the shiga-like toxin SltI gene; and
5′ CAG GTA CTG GAT TTG ATT GTG ACA GTC ATT 3′
which hybridises to the shiga-like toxin SltII gene.
10. The use of the method according to claims 1 to 6 for diagnosing an E. coli infection of a living animal body, including a human, or for the detection of E. coli contamination of consumables, such as meat, milk and vegetables.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/684,085 US20040175723A1 (en) | 1997-04-22 | 2003-10-10 | TaqManTM-PCR for the detection of pathogenic E.coli strains |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK45197 | 1997-04-22 | ||
DK0451/97 | 1997-04-22 | ||
US09/403,690 US6664080B1 (en) | 1997-04-22 | 1998-04-21 | TaqMan™-PCR for the detection of pathogenic E. coli strains |
US10/684,085 US20040175723A1 (en) | 1997-04-22 | 2003-10-10 | TaqManTM-PCR for the detection of pathogenic E.coli strains |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1998/002341 Division WO1998048046A2 (en) | 1997-04-22 | 1998-04-21 | Taqmantm-pcr for the detection of pathogenic e. coli strains |
US09/403,690 Division US6664080B1 (en) | 1997-04-22 | 1998-04-21 | TaqMan™-PCR for the detection of pathogenic E. coli strains |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040175723A1 true US20040175723A1 (en) | 2004-09-09 |
Family
ID=8093715
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/403,690 Expired - Fee Related US6664080B1 (en) | 1997-04-22 | 1998-04-21 | TaqMan™-PCR for the detection of pathogenic E. coli strains |
US10/684,085 Abandoned US20040175723A1 (en) | 1997-04-22 | 2003-10-10 | TaqManTM-PCR for the detection of pathogenic E.coli strains |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/403,690 Expired - Fee Related US6664080B1 (en) | 1997-04-22 | 1998-04-21 | TaqMan™-PCR for the detection of pathogenic E. coli strains |
Country Status (9)
Country | Link |
---|---|
US (2) | US6664080B1 (en) |
EP (1) | EP0994965A2 (en) |
JP (1) | JP2001521394A (en) |
CN (1) | CN1160471C (en) |
AU (1) | AU753277B2 (en) |
BR (1) | BR9808963A (en) |
CA (1) | CA2286310A1 (en) |
NZ (1) | NZ337506A (en) |
WO (1) | WO1998048046A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103207273A (en) * | 2013-03-26 | 2013-07-17 | 南昌大学 | Paramagnetic nano Fe-Co alloy probe based quick detecting method for NMR (nuclear magnetic resonance) food-borne pathogenic bacteria |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1013775A1 (en) * | 1998-12-21 | 2000-06-28 | LUTZ, Hans | Quantitative polymerase chain reaction using a fluorogenic real-time detection system |
EP1077265A1 (en) * | 1999-08-19 | 2001-02-21 | Merlin Gesellschaft Für Mikrobiologische Diagnostika Mbh | Method for the classification of bacteria by genotyping |
DE10004147A1 (en) * | 2000-01-31 | 2001-08-09 | Gsf Forschungszentrum Umwelt | Oligonucleotides for the specific amplification and specific detection of 16S rRNA genes from bacteria |
EP1360324A2 (en) | 2000-08-31 | 2003-11-12 | Mayo Foundation For Medical Education And Research | Detection of varicella-zoster virus |
AUPR050700A0 (en) * | 2000-10-03 | 2000-10-26 | Id+Plus Ltd | Detection method |
US7691571B2 (en) | 2001-01-31 | 2010-04-06 | Mayo Foundation For Medical Education And Research | Detection of bordetella |
WO2002061390A2 (en) | 2001-01-31 | 2002-08-08 | Mayo Foundation For Medical Education And Research | Detection of herpes simplex virus |
DE60228952D1 (en) | 2001-05-07 | 2008-10-30 | Mayo Foundation | Detection of Legionella by PCR and FRET using method |
EP1466011B1 (en) * | 2001-12-19 | 2006-10-11 | Angles D'Auriac, Marc B. | New primers for the detection and identification of bacterial indicator groups and virulence factors |
US20030215814A1 (en) * | 2002-05-17 | 2003-11-20 | Cockerill Franklin R. | Detection of Shiga toxin- or Shiga-like toxin-producing organisms |
US7074598B2 (en) | 2002-09-25 | 2006-07-11 | Mayo Foundation For Medical Education And Research | Detection of vancomycin-resistant enterococcus spp. |
US7365176B2 (en) | 2002-09-26 | 2008-04-29 | Mayo Foundation For Medical Education And Research | Detection of Epstein-Barr virus |
US7074599B2 (en) | 2002-09-27 | 2006-07-11 | Mayo Foundation For Medical Education And Research | Detection of mecA-containing Staphylococcus spp. |
US7427475B2 (en) * | 2003-11-18 | 2008-09-23 | Mayo Foundation For Medical Education And Research | Detection of group B streptococcus |
WO2005113773A1 (en) * | 2004-05-20 | 2005-12-01 | Warnex Research Inc. | Polynucleotides for the detection of escherichia coli 0157:h7 and escherichia coli 0157:nm verotoxin producers |
JP4190562B2 (en) * | 2004-12-08 | 2008-12-03 | 健 山本 | Gene sequence inspection |
NZ571459A (en) | 2006-03-29 | 2011-09-30 | Merial Ltd | Vaccine against streptococcus equi |
ES2797951T3 (en) | 2007-04-04 | 2020-12-04 | Ande Corp | Integrated nucleic acid analysis |
EP2443254A2 (en) | 2009-06-15 | 2012-04-25 | NetBio, Inc. | Improved methods for forensic dna quantitation |
CN101812531A (en) * | 2010-05-06 | 2010-08-25 | 天津朝海科技有限公司 | Escherichia coli detection kit |
KR101982627B1 (en) | 2011-05-12 | 2019-05-27 | 에이엔디이 코포레이션 | Method and compositions for rapid multiplex amplification of str loci |
PL218839B1 (en) | 2011-09-09 | 2015-01-30 | 3G Therapeutics Inc | Method for detection of enterohemorrhagic Escherichia coli (EHEC), a probe for the detection of enterohemorrhagic Escherichia coli (EHEC), the sequence of the amplified fragment of the gene encoding the Shiga toxin, the use of probes and sequences |
US8802371B2 (en) | 2011-09-28 | 2014-08-12 | E. I. Du Pont De Nemours And Company | Sequences and their use for detection and characterization of STEC bacteria |
CN102605068B (en) * | 2012-03-15 | 2013-09-11 | 深圳市生科源技术有限公司 | Pathogenic escherichia coli assay kit and pathogenic escherichia coli assay method |
MD4218C1 (en) * | 2012-06-07 | 2013-11-30 | Национальный Центр Общественного Здоровья Министерства Здравоохранения Республики Молдова | Method for diagnosis of infections caused by enterobacteria producers of beta-lactamases |
CN104865186B (en) * | 2015-05-29 | 2017-08-25 | 重庆大学 | Portable pathogenic bacteria quick determination method |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5041372A (en) * | 1988-11-02 | 1991-08-20 | The United States Of America As Represented By The Department Of Health And Human Services | Probe to identify enteroinvasive E. coli and Shigella species |
US5595874A (en) * | 1986-11-24 | 1997-01-21 | Gen-Probe Incorporated | Nucleic acid probes for detection and/or quantitation of non-viral organisms |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5468852A (en) * | 1992-02-18 | 1995-11-21 | Shimadzu Corporation | Oligonucleotides for detecting bacteria |
EP0669399B1 (en) * | 1994-02-28 | 2003-10-01 | Shimadzu Corporation | Oligonucleotides and method for detecting bacteria |
US6001564A (en) * | 1994-09-12 | 1999-12-14 | Infectio Diagnostic, Inc. | Species specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial pathogens and associated antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories |
CA2203679C (en) | 1994-10-24 | 2010-08-17 | Charles J. Arntzen | Oral immunization with transgenic plants |
-
1998
- 1998-04-21 AU AU80144/98A patent/AU753277B2/en not_active Ceased
- 1998-04-21 BR BR9808963-3A patent/BR9808963A/en not_active IP Right Cessation
- 1998-04-21 EP EP98928211A patent/EP0994965A2/en not_active Withdrawn
- 1998-04-21 CA CA002286310A patent/CA2286310A1/en not_active Abandoned
- 1998-04-21 JP JP54501798A patent/JP2001521394A/en active Pending
- 1998-04-21 CN CNB988044099A patent/CN1160471C/en not_active Expired - Fee Related
- 1998-04-21 NZ NZ337506A patent/NZ337506A/en unknown
- 1998-04-21 US US09/403,690 patent/US6664080B1/en not_active Expired - Fee Related
- 1998-04-21 WO PCT/EP1998/002341 patent/WO1998048046A2/en not_active Application Discontinuation
-
2003
- 2003-10-10 US US10/684,085 patent/US20040175723A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5595874A (en) * | 1986-11-24 | 1997-01-21 | Gen-Probe Incorporated | Nucleic acid probes for detection and/or quantitation of non-viral organisms |
US5041372A (en) * | 1988-11-02 | 1991-08-20 | The United States Of America As Represented By The Department Of Health And Human Services | Probe to identify enteroinvasive E. coli and Shigella species |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103207273A (en) * | 2013-03-26 | 2013-07-17 | 南昌大学 | Paramagnetic nano Fe-Co alloy probe based quick detecting method for NMR (nuclear magnetic resonance) food-borne pathogenic bacteria |
Also Published As
Publication number | Publication date |
---|---|
HK1026002A1 (en) | 2000-12-01 |
CN1160471C (en) | 2004-08-04 |
CN1258320A (en) | 2000-06-28 |
EP0994965A2 (en) | 2000-04-26 |
US6664080B1 (en) | 2003-12-16 |
AU8014498A (en) | 1998-11-13 |
AU753277B2 (en) | 2002-10-10 |
NZ337506A (en) | 2001-08-31 |
CA2286310A1 (en) | 1998-10-29 |
JP2001521394A (en) | 2001-11-06 |
WO1998048046A3 (en) | 1999-07-08 |
WO1998048046A2 (en) | 1998-10-29 |
BR9808963A (en) | 2000-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6664080B1 (en) | TaqMan™-PCR for the detection of pathogenic E. coli strains | |
Witham et al. | A PCR-based assay for the detection of Escherichia coli Shiga-like toxin genes in ground beef | |
Fortin et al. | Use of real-time polymerase chain reaction and molecular beacons for the detection of Escherichia coli O157: H7 | |
Bischoff et al. | Rapid detection of diarrheagenic E. coli by real-time PCR | |
Sharma et al. | Semi-automated fluorogenic PCR assays (TaqMan) forrapid detection of Escherichia coli O157: H7 and other shiga toxigenic E. coli | |
Hara-Kudo et al. | Sensitive and rapid detection of Vero toxin-producing Escherichia coli using loop-mediated isothermal amplification | |
Rahn et al. | Amplification of an invA gene sequence of Salmonella typhimurium by polymerase chain reaction as a specific method of detection of Salmonella | |
US5298392A (en) | Process for detection of water-borne microbial pathogens and indicators of human fecal contamination in water samples and kits therefor | |
US5795717A (en) | Oligonucleotides for detecting bacteria and detection process | |
US5652102A (en) | Assay for enterohemorrhagic Escherichia coli 0157:H7 by the polymerase chain reaction | |
Baranzoni et al. | Detection and isolation of Shiga toxin-producing Escherichia coli (STEC) O104 from sprouts | |
Beneduce et al. | Escherichia coli 0157: H7 general characteristics, isolation and identification techniques | |
Rich et al. | Identification of human enterovirulent Escherichia coli strains by multiplex PCR | |
JPH08294399A (en) | Oligonucleotide for detection of Salmonella and detection method using the same | |
Li et al. | A study on detecting and identifying enteric pathogens with PCR | |
KR100853263B1 (en) | Oligonucleotide primers for the detection of Salmonella and Campillar bacterium, early diagnostic kits including the same, and detection methods using the same | |
JPH078280A (en) | Oligonucleotide for detecting bacteria and detection method using the same | |
Moussa et al. | Multiplex polymerase chain reaction for detection and characterization of shiga toxigenic Escherichia coli (STEC) | |
MXPA99009116A (en) | Taqmantm | |
CA2471230A1 (en) | New primers for the detection and identification of bacterial indicator groups and virulence factors | |
US7041811B2 (en) | Method for detecting Escherichia coli | |
Fliss et al. | Multiplex riboprobes for the detection of virulent Yersinia enterocolitica and simple methods for their preparation | |
Varadaraj | Capacity Building: Building Analytical Capacity for Microbial Food Safety | |
JPH07284400A (en) | Oligonucleotide for detection of Shigella and detection method using the same | |
Anglès d Auriac | Development of microbiological molecular diagnostic techniques for the rapid screening and identification of selected human bacterial pathogens and indicators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION |